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Stultum est in luctu capillum sibi evellere, quasi calvito maeror levaretur
“It is foolish to pluck out one’s hair for sorrow, as if grief could he assuaged hy
baldness”
Marqus Tullius Cicero 
Tusculanarum Disputationum (III, 26)
(http://www.worldofquotes.com/topic/Hair/index.html)
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ABSTRACT
FROM IN-VITRO TO IN-VIVO: CORPORATE DEVELOPMENT AND EFFICACY 
OF A TOPICAL HAIR GROWTH AGENT DERIVED FROM NATURAE EXTRACTS
by Kelly Michael Glynn 
Androgenetic alopecia (male pattern baldness) affects up to 50% of the world’s 
population, propelling the development for a possible treatment. The hair follicle is 
influenced by several genetic and physiologic factors, which, when gone awry, lead to 
androgenetic alopecia. Vascular endothelial and keratinocyte growth factors are 
believed to be promoters of hair growth, as is inhibition of the proteasome complex. The 
cytokine IE -la  is also known to regulate follicle dynamics. The research objective 
described herein was an attempt to develop a botanical blend, which could mediate the 
above biomarkers, be successfully incorporated into a safe topical product and be 
evaluated for in-vivo efficacy. By using an arbitrary scoring system to evaluate in-vitro 
performance, botanical extracts were screened in cell culture and enzyme assays. A 
Design of Experiments analysis, utilizing analyses of variance and multiple linear 
regressions, was performed to derive an optimized blend of Eichochalcone, Saw 
Palmetto, Shiso and Green Rooibos for incorporation into the prototype formulation. 
After passing human irritancy and sensitization testing, these extracts were coupled with 
liposomes to create a final prototype that was also screened for long-term stability. The 
end product was used in a clinical-type trial, assessing its effectiveness to increase scalp
vi
hair density, promote anagen follicle activity and increase the growth rate of the hair 
fiher. The product was henchmarked hy Rogaine® Extra Strength (5% minoxidil) and 
Rovisomes Biotin (commercially available). The twelve-week study involved sixty-nine 
males experiencing varying degrees of androgenetic alopecia who underwent 14” length 
haircuts and a series of digital imaging focusing on a transition zone area of interest.
The three test products significantly increased hair density and the number of anagen 
follicles compared to baseline values. Growth rate was up regulated for users of the 
prototype and Rogaine®. Subjective self-assessment of the products revealed the 
prototype to he the least effective in improving hair quality characteristics, but with no 
significant difference to the other two products. These results indicate the herbal blend of 
Lichochalcone, Saw Palmetto, Shiso and Green Rooibos, in a liposomal base, has the 
potential to be an effective topical treatment for androgenetic alopecia.
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CHAPTER 1 - HAIR AS A BIOLOGICAL ORGAN
A.) INTRODUCTION
From a non-biological view point, hair appears to be nothing more than a 
“symbolic and psychosocial” (Hadshiew, et al., 2004) body part which can be modified to 
bolster self-image and self-esteem from both individual and societal perceptions and 
interactions (Stenn and Pans, 2001; Fans and Foitzik, 2004). In fact, it has been stated, 
“the psychological importance of hair to man is in inverse ratio to its physical function” 
(Ebling, 1976). Unbeknownst to many, human hairs are the only bodily appendage 
which can be manipulated to influence societal relationships and improve self-image 
(Stenn and Pans, 2001). These two attributes have lead to the creation of a multi-billion 
dollar industry (Paus and Cotsarelis, 1999) which attempts to aid men and women with 
their coiffed appearance.
Embedded within the skin, however, is a biological marvel that imparts the 
physical characteristics of length, color, shape and diameter to the hair fiber, which is so 
important to the mirror and society. This marvel is the hair follicle, which retains 
embryonic cues to help create hair fibers throughout an individual’s life (Legue and 
Nicolas, 2005). It does so in a cyclical process in an asynchronous fashion at the level of 
the individual follicle (Stenn and Paus, 2001). Therefore, each human hair follicle can be 
viewed as an independent biological entity that determines whether or not a visible hair 
fiber is present. Through a series of intricate mechanisms, many of which are still 
unknown, hair follicles can become quiescent beyond normal cyclical patterns leading to 
diseased states generic all y termed alopecias. Aside from purely genetic manifestations of
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baldness or aggressive infeetion, states of baldness sueh as alopecia areata (Cotsarelis and 
Millar, 2001; Mulinari-Brenner and Bergfeld, 2001), telogen effluvium, 
chemical/psychological induced baldness (Cotsarelis and Millar, 2001), and androgenetic 
alopecia are all considered temporary states (Mulinari-Brenner and Bergfeld, 2001).
Contrary to perception, however, hair serves several critical biological functions. 
These include defense against insects, camouflage, thermal regulation, sensory detection, 
skin cleansing, and signal transporters (Stenn and Paus, 2001). Additional roles for hair 
include ultraviolet protection and screens to prevent intrusion of foreign particles into 
critical membranes such as the eye. Sexual communication is also influenced hy hair, or 
the lack thereof, in events such as sexual selection in mating preference, identification of 
puberty in adolescents and markers of masculinity in the appearance of chest, pubic and 
heard hair (Camacho, et ah, 2000).
Since hair on all different parts of the hody can serve multiple biological 
functions, the creation and development of the hair fiher must then have its own 
biological apparatus operating under unique controls. Again, this apparatus is the hair 
follicle (Camacho, et ah, 2000), and despite its uniqueness, its multi-mechanistic and 
wondrous operation is concealed from the naked eye. Visibly, the only confirmation of 
its existence is the emergence of the keratinized hair fiher protruding from the epidermal 
surface. When this evidence is no longer present, or when the rate of its regeneration 
capacity begins to diminish, the impact on humans can he monumental, despite being 
painless and non-life threatening. Secondary side effects of hair loss include 
psychological and emotional stress, shame, embarrassment, depression, loss of 
confidence and self-worth, perception of age, and lack of societal acceptance (Hadshiew,
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et al., 2004). These effects have been known to be especially significant in younger aged 
men who suffer from some form of hair loss (Girman, et ah, 1998), hut both genders can 
experience hair loss in some form (Camacho, et al., 2000). So, hair serves a 
physiological, psychological and cosmetic role.
The premise for conducting hair research is to understand the biological
mechanisms that drive fiher growth and fulfill the accessory roles of this fibrous
appendage, and how such mechanisms may relate to other anatomical and physiological
processes. From a purely cosmetic standpoint, however, understanding how hair grows,
and uncovering the hope of how it may he restored in the case of baldness in humans, has
led to a race to be the first to claim success, even if marginal, at reversing a complex set
of interactions which ultimately create this void on the human scalp. A prominent
researcher in hair growth, Dominique Van Neste, has extensively researched the
biological phenomenon and cultural impacts of hair. He states:
As grooming may he controlled hy genetic factors it seems no surprise that hair has 
probably been a material of interest since the very early days of mankind. 
Engravings on the wall of caves and pre-historical sculptures provide the earliest 
representations of hair and clearly tell us about its symbolic dimensions. Hair- on 
the scalp and on the hody -  is communication. It conveys messages about 
ourselves, it tells how we interconnect with social codes and status. Hair is 
everywhere! (Van Neste, 2003).
B.) EMBRYOLOGY OF HAIR
Hair follicle development begins in-utero, at two to three months, on the 
eyebrows, lips, chin, and nose, with later development occurring on the back, abdomen, 
and limbs. Follicle formation appears to he mediated in waves, with distance to the 
preceding follicle being a determinant for new follicle placement. As a result, each 
follicle maintains its own cycle (Serri and Cerimele, 1990). A precursor to follicle
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formation, however, is the establishment of a connective network between epidermal and 
mesenchymal tissues. Signal transmission from mesodermic tissue to embryonic 
ectoderm causes thickening of the ectoderm and formation of the hair placode, which 
emits return signals to the underlying mesenchyme, causing it to condense. Following 
mesenchymal condensation, epithelial placode cells proliferate downward into the 
mesenchymal tissue eventually forming the dermal papilla (Kulessa, et al., 2000). The 
bulbous dermal papilla is the control center from which all-future hair growth regulation 
and cycling will originate (Paus and Foitzik, 2004).
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Figure 1- Development of the Hair Follicle From In-Utero to Maturity (used with permission from  
Dr. Elaine Fuchs 01/08/2009; Rendl et al., 2005, Fig. lA , p. 1911 )
With the basic hair follicle in place, surrounding kératinocytes will begin 
differentiating (Kulessa, et al., 2000) to form eight different concentric layers of the 
follicle. These include: the outer root sheath (ORS) and its companion layer; Henle’s and 
Huxley’s layers; cuticle; and the medulla, cortex and cuticle of the actual hair fiber (Paus 
and Foitzik, 2004).
The intimate signaling during follicle embryogenesis between the epithelial and 
mesenchymal layers drives subsequent hair growth stages in post-natal life. Botchkarev 
and Kishimoto (2003) state:
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Extensive interactions between these two embryologically different hair follicle 
compartments lead to the formation of the hair shaft producing mini-organ that 
shows a cyclic activity during postnatal life with periods of active growth and hair 
shaft formation (anagen), apoptosis-driven involution (catagen), relative resting and 
hair shedding (telogen-exogen).
The continual cross talk between the ectoderm derived epidermis and mesoderm derived
mesenchyme (Serri and Cerimele, 1990) ultimately produces a distinct hair fiber. This
cross-talk is achieved through a combination of: genetic factors (Birch and Messenger,
2001; Midorikawa, et ah, 2004; Ishimatsu-Tsuji, et ah, 2005); a plethora of molecular
signaling (Hoffman, et ah, 1996; Kulessa, et al., 2000; Botchkarev, et al., 2001;
Botchkarev and Kishimoto, 2003); stem cell activity (Alonso and Fuchs, 2003; Blanpain,
et al., 2004; Legue and Nicolas, 2005; Kim, et al., 2006; Zhang, et al., 2006);
neuroimmunoendocrine circuitry (Paus, et ak, 2006); innervation (Hordinsky and
Ericson, 1996); hormones (Thornton, et ak, 1993; Hamada, et ak, 1996; Ellis, et ak, 1998;
Choi, et ak, 2001); and vascularization (Lachgar, et ak, 1996; Lachgar, et ak, 1998;
Sordello, et ak, 1998; Yano, et ak, 2001). The sum of these mechanisms results in
approximately five million hair follicles body-wide, with an estimated 80,000-150,000
follicles dispersed throughout the human scalp (Krause and Foitzik, 2006). After birth,
this number does not increase, whereas the size and shape of each follicle can (Paus and
Cotsarelis, 1999).
Initial fetal hair is termed lanugo hair and is typically shed at eight months in- 
utero, replaced with additional lanugo hairs that last into the fourth month post-partum. 
Vellus unpigmented, fine, short hairs, replace the secondary lanugo hairs, and typically 
cover a majority of the skin surface. Through a prolonged continuation of the above 
mechanisms certain regions of vellus hairs are transformed into terminal hairs, which are
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thicker, longer and pigmented (Jankovic and Jankovic, 2004). The transformation of 
terminal hairs back to vellus hairs on the scalp, and the underlying physiological changes 
occurring within the follicle, is the trademark of androgenetic alopecia.
C.) HAIR ANATOMY AND PHYSIOLOGY
The hair follicle can be divided into three regions: biological synthesis, 
keratinization and the hair fiber portion. Biological synthesis occurs at the hair bulb, 
which encompasses the dermal papilla (Robbins, 1994) and the matrix (Krause and 
Foitzik, 2006). Mesenchyme-derived dermal papilla cells cue the surrounding epithelial- 
derived matrix cells to undergo mitosis during active growth (Philpott, et ak, 1990), 
proliferating at one of the highest rates in the human body, even outpacing some forms of 
cancers (Camacho, et ak, 2000; Krause and Foitzik, 2006). Deposition of melanin from 
melanocytes embedded within the matrix (Paus and Cotsarelis, 1999) also occurs 
resulting in coloration of the cortical cells of the emerging hair fiber. As epithelial cells 
continue to proliferate, they are pushed upward toward the skin surface, where they enter 
the matrix-derived inner root sheath (1RS). The 1RS consists of three distinct layers: 
Henle’s layer, Huxley’s layer, and 1RS cuticle. Henle’s layer contains keratinized sheath 
cells that help form a scaffold to support interior structures. Huxley’s layer, interior to 
Henle’s layer, along with the 1RS cuticle, forms a rigid tube (Camacho, et ak, 2000) that 
confers shape to the upward migrating cells and ultimately shapes the hair fiber (Paus and 
Cotsarelis, 1999). The cells continue to elongate as they enter the zone of keratinization. 
Sulfur transport, mainly in the form of cysteine, into the cells results in the formation of 
disulfide bonds, and eventual keratin synthesis, imparting strength to the hair fiber. 
Keratin synthesis continues until the cell is nearly filled with the fibrous material. As a
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result, transcription and translation cease, nuclear degradation occurs, and the cell is 
dehydrated. As this process occurs throughout the hair shaft cells, the fiber takes on its 
final shape and diameter (Camacho, et ah, 2000; Robbins, 1994). As the hair fiber finally 
emerges from the scalp, it is classified as a “keratin appendage from a follicle which is 
embedded in the dermis,” composed of dehydrated cuticle, cortical and medullary cells 
held together by biological cements (Robbins, 1994).
A
Figure 2- Anatomical Structure of the Mature Hair Follicle 
(http://www.pg.com/sdence/haircare/hair_twh_13.htm)
The aforementioned cuticle is the outermost covering of the hair fiber, formed 
from an interlocking interaction with 1RS cuticles (Serri and Cerimele, 1990). Cuticle 
cells are similar in length to cortex cells, but lack the cortex cells’ elasticity, and impart 
chemical and mechanical resistance as well as moisture regulation to the hair fiber. The 
cortex cells, derived from proliferating matrix, contain interwoven, keratin filaments, 
which resemble a coiled structure microscopically. This longitudinal arrangement offers 
great elastic properties to the hair fiber, compared to protective cuticle cells (Camacho, et 
ak, 2000). The medulla is the innermost section of the hair fiber, and is derived from
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apical dermal papilla cells. In scalp hairs, the medulla is often labeled as not present, but 
in reality, these cells are often porous (Robbins, 1994) and highly vacuolated, making 
their appearance unnoticeable (Camacho, et al., 2000). An additional structure, which is 
involved in constructing the hair fiber and regulating follicle cycling events, is the outer 
root sheath (ORS). The ORS surrounds the hair follicle in its entirety, from the 
uppermost portion in the epidermis remaining with the permanent hair follicle, all the 
way down to the dermally imbedded hair hulh (Serri and Cerimele, 1990). The ORS is 
epithelial-derived, and throughout its length appears to have a multitude of functions 
advantageous for skin repair as well as hair physiological activities. From potential 
harboring of sebaceous glands and epidermal stems cells, to secretion of multiple 
cellular-forming constituents, the ORS offers the skin repair mechanisms following 
injury and/or damage. In addition, the ORS structure contains melanocytes (for 
coloration), Langerhans’ cells (for immune response) and Merkel cells (for neurological 
response), all of which are involved in skin restructuring or aiding the hair follicle to 
respond to infection or sensory stimuli (Paus and Cotsarelis, 1999). External to the ORS, 
and enclosing and separating the entire follicle from the skin epithelial layer, is a 
membrane consisting of extracellular proteins (Rendl, et ah, 2005).
Biological components associated with and/or surrounding the hair follicle 
include: the apocrine gland (perspiration); the sebaceous gland (lipid synthesis and 
secretion); the isthmus (site of sensory fibers); the arrector pili muscle (sympathetic nerve 
fibers synapsed with smooth muscle cells to aid in thermal barrier responses); the 
infundibulum (the region, along with the hair canal, spanning the skin surface to just 
above the sebaceous gland, representing the first body stmctures to be keratinized); and
the bulge (a stem cell repository) (Kanitakis, 2002; Serri and Cerimele, 1990).
D.) STEM CELLS AND THE HAIR FOLLICLE
As concisely summarized by Kolf et al, the stem cell niche:
encompasses all of the elements immediately surrounding the stem cells when they 
are in their native state, including the non-stem cells that might be in direct contact 
with them as well as ECM (extracellular matrix) and soluble molecules found in 
that locale. All of these act together to maintain the stem cells in their 
undifferentiated state. It is assumed that certain cues must find their way into the 
niche to signal the stem cells that their differentiation potential is needed for the 
regeneration or repopulation of a tissue (Kolf, et ah, 2007).
For the hair follicle, the bulge is the stem cell niche, supporting both hair regeneration
and the skin epithelium (Alonso and Fuchs, 2003) and marks the end of the permanent
hair follicle (Serri and Cerimele, 1990). The portion of the hair follicle inferior to the
bulge undergoes remodeling processes throughout the hair cycles. Downward growth
into the dermis, during active growth, is accomplished through epithelial-mesenchymal
communications between the permanent and regenerating portions of the follicle.
Derived from and residing in the ORS, the bulge was found to retain its relative position
of origin in individuals ranging in age from two weeks to twenty-one years (De Viragh
and Meuli, 1995).
Since the dermal papilla is referred to as the command center of the hair follicle 
and is surrounded by highly proliferating matrix cells, initial hypotheses stated hair 
follicle stem cells should logically reside somewhere in the same vicinity (De Viragh and 
Meuli, 1995). In work done as early as 1994, however, evidence pointed to stem cell-like 
activity occurring from a region in approximation to the arrector pili muscle (Rochat, et 
ah, 1994). Further research verified the bulge was the location harboring stem cells to be 
used to regenerate the active growth stage for the hair follicle, and possibly for aiding in
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epidermis repair following tissue damage, since these epithelial stem cells can reproduce 
sebaceous glands and skin layers when these components are destroyed (Paus and 
Foitzik, 2004). Furthermore, when the colony-forming ability of kératinocytes isolated 
throughout the hair follicle was examined, cells isolated from the bulge were able to 
generate 95% of the colony-forming cells in culture, while only 5% of colony-forming 
cells were attributed to the matrix region. Also, the colony forming kératinocytes showed 
no increase in growth potential when co-cultured with papilla fibroblasts, an indication 
that there may be a certain level of independence between the two follicle cell types and 
how they regulate hair fiber growth (Kobayashi, et ak, 1993).
Within the basal layer of the epidermis, stem cells also reside, which through 
division, upward movement, and terminal differentiation result in mature skin cells. It 
has been suggested that the bulge stem cells may be the multi-potent progenitors of the 
epidermal stem cells since: epidermal stem cells have no identifiable niche within the 
epidermis; bulge stem cells exhibit slower cycling times than epidermal stem cells; and 
retention of radioactive thymidine is longer within bulge cells, indicative of the cells not 
undergoing rapid cell cycle/mitosis events. Daughter cells derived from bulge stem cells 
eventually differentiate to assist in the formation/maintenance of the hair follicle matrix, 
the sebaceous gland, and the basal layer of the epidermis (Alonso and Fuchs, 2003).
A prominent theory as to how the bulge drives hair follicle regeneration is known 
as the bulge activation hypothesis. The premise is the mesenchymal dermal papilla emits 
a signal to the bulge stem cells, which in turn, begin sending stem cells to the hair bulb 
region. These mobile signal carriers create rapidly dividing kératinocytes, which will 
form/reform the hair bulb, and through a series of additional stages, new hair fibers are
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produced (Alonso and Fuchs, 2003; Camacho, et a l, 2000; Stenn and Pause, 2001). The 
length of that fiber will correspond to the number of cell divisions taking place, and when 
the proliferative capability of these is reached, catagen induction begins (Camacho, et a l, 
2000).
Recent research has also indicated the matrix stem cells, derived from the bulge, 
are highly organized and compartmentalized with each sector responsible for forming a 
certain portion of the hair fiber. At the inner core of the matrix, multipotent stem cells 
reside which produce daughter cells that give rise to transient progenitors of the various 
structures of the hair fiber. These progenitors are in the layer external to the multipotent 
stem cells. The third and final concentric layer consists of post-mitotic ancestors of the 
transient cells, whose function is to construct the columns of the hair bulb which will be 
used to construct the different components of the hair fiber. This organizational pattern 
creates a radial distribution within the bulb. How cells align along the central vertical 
axis of the bulb determines each cell’s fate, giving rise to the 1RS, hair fiber cuticle or the 
medulla (Legue and Nicolas, 2005).
Stem cells are necessary for maintaining cellular and physiological balance and 
also for initiating repair mechanisms and tissue regeneration following wounding. For 
hair growth regulation, stem cells and their niche are critical for re-initiating the active 
growth phase in the hair cycle. For this reason, characteristics of the bulge and its stem 
cells include: 1.) The bulge is anatomically formed postnatally following the initial 
growth stage; 2.) Basal layers within the bulge are attached to a basement membrane, 
while several genes, responsible for producing cytoskeletal, extracellular matrix, cell 
adhesion molecules and proteins are active within; 3.) The niche housing the stem cells
11
within the bulge is partitioned asymmetrically; 4.) Isolated stem cells are able to 
reproduce several generations of clones in culture, as well as reproduce hair follicles and 
sebaceous glands; 5.) Stem cells respond to external cues to initiate regeneration events;
6.) Once in the hair bulb region, stem cells undergo specific spatial organization to 
properly reconstruct the hair follicle and eventual hair fiber. As a whole, these attributes 
indicate the bulge is a pertinent player in hair growth and skin function (Blanpain, et al., 
2004; Legue and Nicolas, 2005).
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CHAPTER II: HAIR CYCLES 
A.) ANAGEN, CATAGEN, TELOGEN & EXOGEN
One of the most interesting aspects of the hair follicle is its cyclic nature, divided 
among stages of active fiher growth (anagen), growth cessation and apoptosis of the 
temporary follicle (catagen), and a period of rest and/or remodeling (telogen) (Muller- 
Rover, et ah, 2001; Pans and Foitzik, 2004; Rendl, et al., 2005; Rohhins, 1994). As 
technology has advanced to observe follicle morphogenesis, and the complexity of these 
cyclic events has come to he understood, the hair follicle has become “an attractive 
system for studying major biological phenomena” (Stenn and Pans, 2001).
Anagen begins with the cues to start the reconstruction of the follicle hulh and 
ends when active growth ceases and additional cues are received to begin the 
deconstruction of the same bulb. Anagen occurs in six distinct steps (Müller-Rôver, et 
al., 2001), hallmarked by the rapid proliferation of matrix cells, active melanin deposition 
via melanocytes and keratinization of epidermally progressing cells, all contributing to 
the emergence of the characteristically distinct hair fiber (Rohhins, 1994; Stenn and Pans, 
2001). The actual molecular cues, which initiate this growing process, remain obscure; 
however, the anatomical events occurring to lead to active growth resemble those events 
happening during embryonic follicle development. Epithelial cells divide in a downward 
fashion to reach the dermis, where dermal papilla cells anchor to a basement membrane. 
Upon reaching their end point, growth begins in an upward and outward fashion with the 
development of the 1RS and hair shaft (Stenn and Paus, 2001).
The processes initiating anagen include trauma and/or wounding of the hair 
follicle, hair plucking, and chemical influence. Merely cutting the hair fiber does not
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induce anagen events (Stenn and Paus, 2001). In addition, the same cellular and 
molecular pathways involved during embryonic follicle development are believed to take 
part in the governing of anagen initiation and progression throughout life (Cotsarelis and 
Millar, 2001).
Approximately 80-90% of a human’s scalp hairs are in the anagen stage (Robbins, 
1994), which lasts between two to five years. The factor that determines the length of a 
single hair fiber then is the duration of time the follicle spends in the anagen phase 
(Mulinari-Brenner and Bergfeld, 2001), while the diameter of a hair fiber is determined 
by the size of the dermal papilla. A larger dermal papilla generally contains more 
proliferating matrix cells. The dermal papilla volume is created during the first stages of 
anagen (Cotsarelis and Millar, 2001). The shape of the hair fiber is ultimately determined 
by the shapes of the ORS and 1RS, through which the upward migrating cells are 
funneled (Camacho, et al., 2000). In many cases, the anagen portion of the hair cycle 
will function normally in the scalp through approximately ten progressions, which 
corresponds to roughly forty years of age (Krause and Foitzik, 2006).
All of the work done during anagen is destroyed during the eight stages of catagen 
(Müller-Rôver, et al., 2001) defined as “highly controlled involution of the hair follicle 
resulting in apoptosis and terminal differentiation’’ (Krause and Foitzik, 2006). The 
characteristic signs of apoptosis (cell shrinkage, blebbing, nuclear condensation, and 
eventual cell fragmentation) are all observed in cells of the follicle (Botchkareva, et ah, 
2006). The switch from anagen to catagen is again somewhat of a mystery in terms of 
causation, molecular signaling and genetics, but certain events, such as chemical 
application, trauma, and environmental factors have been found to invoke this regressive
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phase (Stenn and Paus, 2001).
During catagen, the temporary portion is disassembled by means of regulated cell 
death occurring in certain follicle structures. In addition, the dermal papilla separates 
from the follicle bulb (Stenn and Paus, 2001). The size of the entire follicle is also 
diminished, as is the position of the follicle. Follicles may reach into the subcutaneous 
fat layer during anagen, while the same post-catagen follicle transcends into the dermal 
tissue (Cotsarelis, 1997).
One of the most interesting aspects of apoptosis during catagen is it occurs in 
waves, beginning with the area of melanin deposition in the bulb, spreading to the hair 
matrix, then the ORS and 1RS, and finally converging on the hair shaft (Botchkareva, et 
al., 2006). Even more intriguing, however, is dermal papilla fibroblasts do not undergo 
apoptosis, nor do most bulge cells, at anytime during the hair cycles. This demonstrates 
that these cell types are critical for future regeneration events in subsequent growth 
cycles (Botchkareva, et al., 2006; Cotsarelis, 1997).
Considering the highly controlled state of catagen, a relatively small percentage of 
scalp hairs are in this stage at any given time, roughly 1-2% (Robbins, 1994).
Furthermore, it is expedient, lasting anywhere from three to six weeks (Mulinari-Brenner 
and Bergfeld, 2001). The catagen events of the hair follicle are “to delete the old hair 
shaft factory and to bring the inductive machinery of the cell to a point where a new 
follicle can form, utilizing once again, the stem cells of the bulge and the inductive 
powers of the papilla” (Stenn and Paus, 2001).
The cycle in which most hairs spend their time, second to anagen, is telogen. This 
is the resting phase of the follicle, or as alternately proposed, a “pre-regeneration” state of
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anagen (Camacho, et al., 2000), or an anagen brake (Stenn and Paus, 2001). By the time 
a follicle has entered into telogen, epithelial kératinocytes have surrounded compacted 
dermal papilla fibroblasts, which have minimal proliferative activity (Paus and Foitzik, 
2004). Even though follicle activity has diminished in telogen, relative to anagen and 
catagen, the follicle still contains the necessary cell populations to generate a new follicle 
and fiber in the next anagen cycle. These include epithelial stem cells, ORS 
kératinocytes, and melanocytes (Camacho, et al., 2000). The dermal papilla is terminal 
to and adjacent to the hair germ (the base of the quiet follicle) and the entire structure is 
located in approximation to the arrector pili muscle, well into the dermal layer (Camacho, 
et al., 2000; Stenn and PauS; 2001). Residing in the hair shaft is the club hair, or dead 
hair (Paus and Cotsarelis, 1999) to which the root sheaths have attached. The bulb, 
matrix and dermal papilla are now separated from the shaft, effectively preventing any 
further growth of the hair fiber. The club hair will eventually be shed, in the cycle known 
as exogen, which is believed to be distinct from the anagen cycle, even though the two 
events can occur simultaneously. A club hair will still reside within the follicle, while a 
new anagen phase has started rebuilding the lower, temporary portion of the regenerative 
follicle. In fact, it has been proposed, the cycle of exogen encompasses the factors that 
anchor the club hair into the follicle, and what molecular events take place to release the 
club hair from the shaft (Stenn and Paus, 2001). On average, an individual loses 
anywhere from 50-100 hairs per day as a result of the exogen event (Robbins, 1994).
The percentage of scalp follicles in telogen ranges from 10-20% (Robbins, 1994), 
and lasts, on average, three to nine months (Camacho, et ah, 2000). From a historical 
research perspective, little investment of time has been put into telogen research, and as
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such, the magnitude of molecular biomarkers involved in this stage is still unknown 
(Stenn and Paus, 2001).
a .
Figure 3- Progression and cyclic nature of hair follicles (used with permission from the New England 
Journal of Medicine 01/12/2009; Pans and Cotsarelis, 1999, Fig. 2, p. 493.)
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B.) TYPES OF HAIR ABNORMALITIES
It is apparent the alterations in the hasic operations of the hair cycles will lead to 
some type of hair disorder. In addition, since the number of follicles an individual 
possesses is an emhryogenic determined entity, the mechanisms of operation in each 
follicle will determine hair abnormalities (Mulinari-Brenner and Bergfeld, 2001). For 
example, if anagen is excessively prolonged, hypertrichosis or hirsutism can result, both 
of which are excessive hair growth disorders. When the anagen cycle is continually 
shortened during successive cycles, or if telogen is extended, alopecia will result. 
Different associated factors can drive a multitude of other hair disorders, including 
alopecia areata (patchy hair loss either on the scalp or throughout the body caused by an 
autoimmune malfunction); anagen effluvium (sudden shedding of actively growing hair 
as is observed in chemotherapy patients); telogen effluvium (abnormal number of 
follicles induced into telogen often due to certain drugs/medications or fever); permanent 
alopecia (entire follicle is destroyed due to infection, autoimmune disorders or skin 
cancers); and androgenetic alopecia (influenced by the androgenic steroids testosterone 
and dihydrotestosterone [DHT] resulting in characteristic balding patterns on the scalp). 
With the exception of genetic deletion and follicle organ deletion, malfunctions in one or 
more of the cycling events, or aberrant factors and/or influences involved within a cycle, 
will result in an abnormal manifestation of hair growth or hair loss (Hamada and Randall, 
2006; Hibberts, et al., 1998; Mulinari-Brenner and Bergfeld, 2001, Paus and Cotsarelis, 
1999).
The remainder of this review will focus mainly on androgenetic alopecia (AA), 
which is the most prevalent form of hair loss on the scalp (Hoffman, 2003) accounting for
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approximately 95% of those individuals suffering from some type of hair growth defect 
(Choi, et ah, 2001). It is estimated between 40-50% of the world’s population is afflicted 
with this disease (Krause and Foitzik, 2006; Robbins, 1994) with up to eighty million 
Americans experiencing hair loss (Leavitt, 2003). It can affect both males and females 
(Mulinari-Brenner and Bergfeld, 2001) and children as young as six years of age have 
also been known to be susceptible (Tosti, et al., 2005). In regards to intervention, AA is a 
non-permanent form of baldness (Paus and Cotsarelis, 1999) since the follicle does 
remain embedded within the dermis and continues to cycle even in the absence of a 
visible hair fiher (Mulinari-Brenner and Bergfeld, 2001). The biological complexity of 
the hair follicle in terms of operational control is still a mystery waiting to be solved, 
while the physiological function in humans has taken on a largely cosmetic role. The 
hope for restoring hair growth remains limited with surgical repair via hair 
transplantation being the only permanent fix to date (Leavitt, 2003). Hope for better 
success, by easier means, will come if only the mystery of biological complexity is 
unraveled. Understanding these mechanisms and the influences associated with them 
may eventually lead to that cosmetic milestone.
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CHAPTER III- FACTORS INVOLVED IN HAIR GROWTH/LOSS
A.) HORMONES
Two major contributing factors to A A are androgens and genetic predisposition 
(Ellis, et al., 1998). When the synthesis of androgenic steroids begins with cholesterol, 
several weaker intermediate hormones are produced which can and are converted to more 
potent forms via enzymes. The major androgenic steroid circulating throughout the body 
is testosterone, while the still more potent steroid is dihydrotestosterone (DHT) converted 
from testosterone by the enzyme 5a-reductase (5a-R). Androgen potency is determined 
by its binding affinity to the androgen receptor (AR) within a cell’s cytoplasm. A further 
dimension to consider is free-circulating androgens. Sex-hormone-binding-globulin 
(SHBG), binds almost 70% of available testosterone, while albumin takes hold of another 
19%. That leaves approximately 10% of available testosterone as free circulating 
hormone. It still remains unclear as to whether or not bound testosterone, onto either 
protein, can be active. Once an androgen binds the AR, the complex shuttles to the 
nucleus where it exerts its effects via gene transcription or suppression. The primary 
androgens related to hair follicle physiology are testosterone and DHT, though additional 
hormones and factors can certainly play a role in the regulation of hair growth/loss.
These include levels of available hormones, levels of conversion enzymes, the number of 
androgen receptors present within a cell and/or tissue and the influence of the androgen 
complex on genes directly involved in hair growth modulation (Hoffmann, 2003).
Some of the most interesting research conducted on hair growth regulation has 
been the realization that androgens, particularly DHT, have different modulatory 
properties throughout the body and even on the scalp (Hibberts, et ah, 1998; Hoffmann,
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2003; Stenn and Paus, 2001; Thornton, et al., 1993). For instance, the occipital scalp is 
androgen insensitive, while the frontal, parietal and coronal scalps are all androgen 
sensitive. The scalp vertex is androgen sensitive but androgen independent. The axillary 
portions of the body are androgen dependent whereas the eyebrows and eyelashes are 
androgen insensitive (Stenn and Pans, 2001). So even though a majority of the body is 
covered by hair, either terminal or vellus, not all hairs are affected in the same way by 
androgens.
Extensive research has been done in an attempt to explain how different body 
locales respond to androgens. Work done by Hibberts, Howell and Randall (1998) found 
the number of androgen receptors in dermal papilla fibroblasts was significantly higher in 
follicles extracted from balding scalp tissue compared to non-balding scalp tissue, while 
the androgen binding affinity from both regions was identical, as was the protein content 
of both receptors. Such a discovery implies the number of androgen receptors in a given 
area may have a significant impact on hair growth. However, expression of androgen 
receptor mRNA has also been found throughout the hair follicle in both balding and non- 
balding individuals (Asada, et al., 2001), indicating more is needed than just a large 
quantity of androgen receptors to precipitate a balding condition.
Additional factors influencing the expression and/or control of the AR include 
phosphorylation of specific serine residues in the AR protein. When androgen is bound 
to the AR, phosphorylation of these residues increases. Attention to the phosphorylation 
of serine 213 in the AR protein is especially intriguing since it may be involved in certain 
developmental processes, and has been shown to promote the degradation of the AR 
(Taneja, et al., 2005). The discovery of isoformic co-activators for AR transcription has
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also hinted at explaining the different responses to androgens throughout body tissue.
The short isoform, ARA70(3, was observed only in the dermal papilla portion of the 
follicle, and its expression was reduced in balding tissue compared to non-balding tissue 
(Lee, et ah, 2005). It is interesting to surmise that the co-activator for the AR is upstream 
from AR transcription. Simultaneous expression of both the co-activator and receptor 
protein could limit hair growth in the different scalp tissues by negatively regulating 
dermal papilla proliferation signals.
When beard dermal papilla cells (androgen dependent and sensitive) were 
compared to non-balding scalp dermal papilla cells (androgen independent and/or 
insensitive) for the conversion of testosterone to DHT, via uptake of radiolabled 
testosterone, it was discovered the beard cells only converted testosterone to DHT, not 
the scalp cells. So not only is the AR important for hair growth modulation, but the 
presence of the converting enzyme, 5a-R, is also a critical factor (Thornton, ct ah, 1993).
The 5a-R enzyme has two isoforms, 5a-Rl and 5a-R2, which have been found to 
have specificity within the cell as well as in tissue activity (Stenn and Paus, 2001). 
Epithelial cells of the hair follicle have an abundance of 5a-R l, compared to a limited 
amount of 5a-R2, while the dermal papilla contains mRNA for 5a-R2 almost exclusively. 
The quantities for both of these isoforms were not different in balding and non-balding 
cases (Asada, et al., 2001). Since the dermal papilla appears to solely express 5a-R2 
mRNA, and is the command center of the actively growing hair follicle, it seems 
reasonable to believe the 5a-R2 isoform is an essential enzyme for androgen 
metabolization where androgen influence plays a significant role in hair growth (Asada, 
et ah, 2001 ; Hoffmann, 2003), and that the main site for androgen activity is in the
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dermal papilla of the hair follicle (Hamada, et ah, 1996).
Additional research examined the levels of androgens in hair from the different 
zones (balding versus non-balding) of the scalp. Serum levels of androgen were also 
tested. Levels were compared within individuals and to controls (non-balding subjects). 
Vertex DHT was higher in balding subjects versus non-balding individuals, but no real 
difference in DHT levels was found to exist between balding and non-balding zones from 
the same subject. Serum levels of both DHT and testosterone were also higher in balding 
participants compared to non-balding participants (Bang, et ah, 2004).
Besides testosterone and DHT, estrogen and estrogen intermediates are also 
involved in hair regulation in both males and females. Ohnemus et ah, (2006), in their 
review of estrogen function, state; “estrogens and estrogen metabolism are at least as 
important as androgens in male and female hair biology.” Reasons listed for this 
premise include inhibition of hair re-growth in mice when estrogen is applied topically, 
which directly opposes the common practice of topical application of estrogens for hair 
growth stimulatory effects in women suffering from androgenetic alopecia. Such an 
anomaly points to another complex mode of influence, further compounded by species 
specificity. In addition, research is also referenced which points to estrogens having the 
capability of squelching androgen metabolism, even in the dermal papilla, to the point 
that the amount of DHT produced, following testosterone stimulation, is reduced. The 
enzyme aromatase, which can convert testosterone to the less potent 17p-estradiol, has 
also been isolated from cells which have active AR expression occurring, suggestive of a 
complex regulatory role between the two hormone classes, which when gone awry, may 
be manifested in some hair disorder. This complexity is further complicated by research
23
showing hormone receptors of the different classes can communicate with each other, 
leading to alterations of the individual hormonal cascades and regulation of gene 
expression (Ohnemus, et ah, 2006).
The hormone prolactin and its receptor were also found to exist in human hair 
follicles, and that treatment with exogenous prolactin inhibited cultured follicle growth, 
while endogenous prolactin, and its receptor, expression increased as follicles advanced 
into the catagen cycle. The region of prolactin activity appears to be limited to epithelial 
cells in the follicle since mesenchyme derived dermal papilla cells exhibited no presence 
of the hormone, or its receptor (Foitzik, et ah, 2006).
In terms of hormones, the hair follicle exhibits a high degree of complexity, just 
compounding the difficulty of understanding how this miniaturized organ operates. Even 
though common male patterned baldness bears the moniker of the androgen steroid, 
much more is in play in the regulation of hair growth, from conversion enzymes to 
intermediates to expression locations.
B.) GENETICS AND GENES
Due to the high degree of integration between the different physiological systems 
regulating hair growth, and how the phenotype or clinical appearance can manifest itself 
over time, balding and non-balding conditions are polygenetic traits, which are reached 
upon on a threshold crossing of genetic events gone awry. Birch and Messenger (2001) 
examined first and second generation inheritance patterns for balding and non-balding 
males. After five hundred seventy-two men were studied, the researchers concluded: 
balding is common in Caucasian males; with increasing age, baldness also increases 
regardless of what stage the balding pattern is; if a balding condition manifests itself
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before the age of thirty, the probability is high for the father of these individuals to also 
be bald; if men live long enough, they will go bald; males who are resistant to balding 
typically come from non-balding families; and the female balding condition possesses a 
higher threshold state since androgens contribute to baldness and are typically at lower 
levels in females.
Several gene expression profile studies have been conducted comparing the 
balding and non-balding traits. Macroarray research that examined expression levels of 
1185 genes, ranging in function from cell cycle regulation to apoptosis, discovered nearly 
ten percent [107] of the genes were alternately expressed in balding subjects. Genes 
involved in signal transduction and cell cycle regulation both had decreased expression 
levels in dermal papilla cells from balding sites. Furthermore, fourteen growth factor 
genes also exhibited decreased expression. Taken together, these findings indicate the 
balding follicles were functionally inactive (Midorikawa, et ah, 2004).
A microarray analysis comparing male and female gene expressions revealed 
1436 genes were common to both genders, while ninety-seven genes showed differential 
expression between the two sexes, with a majority [89] at higher levels in males, and only 
eight were positively up regulated in females. What state of balding the test subjects 
were in was not mentioned, but since hair fiber extractions included the upper portion of 
the ORS sheath, follicles were most likely in the anagen cycle (Kim, et al. 2006).
A murine microarray study was done, whose hair follicle cycles can be 
synchronized by epidermal dépilation via waxing. As the hair cycle stages progressed, 
expression patterns were compared to non-depilated skin tissue. Some key findings of 
this research show twenty-three days post dépilation, expression patterns returned to
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baseline levels relative to the non-depilated tissue expressions. Following the hair 
removal event, genes involved in inflammation response and anagen initiation were the 
main factors, while in the mid-late anagen cycle, keratin related genes were active, all of 
which correspond to the regenerative events of hair fiber formation (Ishimatsu-Tsuji, et 
al., 2005).
In regards to specific gene events, Ellis, Stebbing and Harrap (2001), analyzed 
androgen receptor gene polymorphisms in balding and non-balding males. They 
determined a restriction fragment length polymorphism, StuI, residing in exon one of the 
AR gene, “is a necessary, but not sufficient component of the polygenic predisposition to 
male pattern baldness.” In young men with baldness, 98% percent of the subjects 
possessed this marker, while older, balding males also exhibited polymorphism to a high 
degree. Those without this particular polymorphism were not likely to go bald. In cases 
where the marker was present, but baldness was not, the balding threshold may not have 
been reached yet, and/or the other required polygenetic dispositions were not present in 
those individuals. This was later corroborated on a different ethnic group, which showed 
the dual band polymorphism in balding males resulted from a single nucleotide base 
change (adenine to guanine) in the first exon of the X chromosome (Levy-Nissenbaum, et 
ah, 2005).
The 5a-Reductase gene would also be a logical target for researchers hoping to 
understand the genetics involved in baldness and/or hair growth regulation. Since the 5a- 
reductase enzyme has two isoforms, there are two separate genes as well. SRD5A1 codes 
for the 5a-Rl enzyme, and is located on chromosome five, whereas SRD5A2 codes for 
the 5a-R2 form and is on chromosome two. What research has uncovered though, is both
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genes have elevated expression levels in the frontal scalp for both men and women, but 
no significant difference in distribution patterns could be discerned for both genes 
between balding and non-balding states. The implication here is the 5a-R gene or 
enzyme variability is not a contributing factor to a balding disposition. In addition, since 
sons of balding fathers also tended to display baldness in this study, the likelihood of a 
simple X-linked mode of inheritance appears unlikely. With all factors considered, a 
polygenetic mechanism produces the balding phenotype (Ellis, et ah, 1998; Levy- 
Nissenbaum, et ah, 2005).
The hairless gene, when defective in mice, will produce normal looking hair 
follicles at birth. When the first catagen cycle occurs, however, the entire mouse 
becomes bald with dermal cysts forming in the follicle. In regards to humans, alterations 
in hairless leads to an entire body devoid of hair (Camacho, et ah, 2000). The dermal 
papilla is separated from the hair shaft and improper catagen deconstruction of the 
follicle results in loss of recovery for future hair growth events. Another human hair 
deficiency, identified as MIM: 601705, is synonymous with expression of the recessive 
nude phenotype in mice. Despite the presence of a hair follicle, the hair shafts cannot 
break the epidermal barrier, resulting in complete baldness (O’Shaughnessy and 
Christiano, 2004).
When the gene expression profiles are tallied, there is supporting evidence for 
over one hundred seventy-nine genes, involved in hair growth functions (Ishimatsu-Tsuji, 
et ah, 2005; Kim, et ah, 2006; Midorikawa, et ah, 2004) and at least one hundred 
different proteins expressed in the hair follicle (O’Shaughnessy and Christiano, 2004). 
Such a large number just re-emphasizes the complexity of the network controlling this
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“miniaturized” organ and the uncertainty of which factor(s) is absolutely essential for 
initiating the process of hair loss. Through a thorough examination of genetic analysis, 
molecular factors, environmental influences, and inferential implications from both in- 
vitro and animal studies, the intricacy of the hair follicle may be solved. Even then it is 
still unknown if it can be manipulated in order to restore the proper balance ensuring a 
cosmetically, socially and mirror image pleasing perception and appearance.
C.) MOLECULAR MARKERS
Since the hair follicle has come to be understood as a complex mini-organ, it has 
garnered much interest “for studying major biological phenomena” (Stenn and Paus, 
2001) in addition to hair biology research. Cell cultures of hair follicle kératinocytes and 
dermal papilla fibroblasts are now commercially available, and isolation and culturing 
techniques of surgically extracted follicle cell types are well established (Havlickova, et 
ah, 2004; Stenn and Paus, 2001; Randall, 1996; Warren and Wong, 1994; Philpott, et ah, 
1990; Buhl, et ah, 1989; Lattanand and Johnson, 1975). The use of such cell types and 
cultures, along with animal models, have aided in identifying at least eighty-five growth 
factors, transcription factors, cytokines and various protein and receptor constituents 
involved in hair growth regulation (Stenn and Paus, 2001).
Two of the growth factors involved with the anagen stage of hair follicle (HP) 
cycling are vascular endothelial growth factor (VBGF) and keratinocyte growth factor 
(KGF). VEGF expression from hair follicle dermal papilla cells (HFDPC) is believed to 
promote vascularization to the re-developing hair bulb during the telogen-anagen switch 
(Lachgar and Moukadiri, et ah, 1996). This vascularization is believed to be a 
reconnection of blood vessel networks (angiogenesis) (Yano, et ah, 2001), which has
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been found to be active during anagen stages (Mecklenburg, et at., 2000). VEGF is a 
critical growth factor for initiating angiogenic events (Lachgar, et ah, 1999; Lachgar, et 
ah, 1998; Shweiki, et ah, 1993) and minoxidil treatment on human dermal papilla cells 
showed up-regLilation and elevated expression of VEGF mRNA and protein (Lachgar, et 
al., 1998).
KGF, also known as fibroblast growth factor-7, is produced by HFDPCs and has 
been shown to mediate keratinocyte proliferation, with maximal expression occurring 
during the anagen V sub-stage in murine studies, which corresponds to a period of rapid 
hair fiber synthesis (Kawano, et ah, 2005). Elevated expression levels of KGF receptor 
mRNA has been observed in rat embryo follicugenesis, while injections of recombinant 
KGF resulted in marked hair growth, as did keratinocyte proliferation and follicle 
hypertrophy (Danilenko, et ah, 1995). KGF is also an attractive research growth factor 
target since it potentially involves mesenchymal-epithelial cross talk-HFDPC secretions 
acting on kératinocytes and affects hair morphology in KGF null mice (Guo, et ah, 1996; 
Finch, et ah, 1989), which is prevalent in HF dynamics.
Inhibition of the proteasome has also been found to be a stimulatory mechanism 
for hair growth, with targeting of the same molecular markers initiating bone-remodeling 
events. Specifically, compounds that can suppress proteasome function suggestively 
promote hair follicles to enter the anagen hair cycle phase, thereby promoting hair fiber 
growth. The proposed mechanism by which this occurs is through mediation of the 
Hedgehog, Bone Morphogenic Protein (BMP) and Wnt signaling cascades. Even topical 
application of aldehydic proteasome inhibitors induced anagen and resulted in significant 
hair growth versus a negative control (Mundy, et ah, 2007). Sonic hedgehog is active
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during embryonic development of the follicle (Dlugosz, 1999) and has been found to be 
critical for subsequent hair fiber synthesize (Paladini, et ah, 2005; St. Jacques, et ah, 
1998). The presence of Wnt signaling leads to activated P-catenin and target gene 
transcription (Huelsken and Behrens, 2002), which has been sbown to promote tbe switch 
from telogen follicles to anagen follicles and prolonged anagen function (Huntzicker and 
Oro, 2008). Furthermore, it has been sbown P-catenin activates VEGF, associated in 
angiogenesis, in certain colon cancers (Levy, et ah, 2002), an element already revealed as 
pertinent to hair growth.
Expression of the cytokine IE -la  is limited to HF kératinocytes, including those 
in the HF matrix (Hoffmann, et ah, 1997; Xiong and Harmon, 1997; Philpott, et ah,
1996). The exact role of IE -la  in HF dynamics is still elusive since some studies have 
demonstrated inhibitory events (Hamada, et ah, 2003; Mabe, et ah, 1996) wbile more 
recent research portrays a positive influence for up-regulating known hair growth 
initiating factors (Boivin, et ah, 2006).
D.) CLINICAL METHODS
The use of liposomes in hair loss treatment applications has grown, since it has 
been sbown tbat topical delivery of liposome-based formulations can penetrate into tbe 
skin witb selective targeting to the HF (Jung, et ah, 2006). Incorporated into the vesicles 
can be a wide range of active ingredients, varying in size and hydrophilicity (Li and 
Hoffmann, 1997; Li and Hoffmann, 1995) that could potentially influence specific 
molecular biomarkers and/or cellular constituents within HF structures. These markers 
could include VEGF, KGF, IE -la  and the proteasome. Incorporating botanical extracts 
into liposomes, to treat androgenetic alopecia, is an attractive methodology to compete
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with the only two approved Food and Drug Administrations treatments, Fropecia and 
Rogaine® (Sawaya, 1998). In addition, by using botanicals, the negative aspects of using 
animal-derived ingredients, availability issues, range of effectiveness (Aburjai and 
Natsheh, 2003) and reduced costs, relative to total health care costs (Saikia, et ah, 2006) 
are minimized. Furthermore, the drive to develop hair loss treatments will be propelled 
by diminished male self-image resulting from hair loss, increasing hair loss in females 
and an increasing aging population (Euromonitor, 2007).
From a current clinical perspective, the methods available to study hair 
loss/growth patterns involve modifications of the classic trichogram (“forceful hair 
pluck”, Sperling, 1991) enhanced by epiluminescence photography and digital imaging, 
aptly named the phototrichogram. The primary parameters typically followed in hair loss 
interventions are hair density and hair fiber diameter. Secondary, are the hair growth rate 
and the anagen-telogen ratio (Hoffmann, 2001). Successful topical hair growth 
treatments should be able to either individually or in combination: 1.) Arrest 
miniaturization of the follicles; 2.) Promote terminal hair formation while reducing vellus 
hairs; 3.) Promote actively growing hairs (anagen); 4.) Enhance the growth rate of 
actively produced hair fibers and/or increase hair fiber diameters (Hoffmann and Van 
Neste, 2005).
E.) RESEARCH OBJECTIVE
As discussed, the complexity of hair growth regulation and malfunction is 
intricate. Testing all aspects would be time consuming and cost prohibitive from a 
corporate perspective, whose main goal is to develop, market and sell an efficacious
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product. As a result, the hair research team originated a muiti-faceted bioassay screening 
approach, targeting established and novel factors associated with hair growth and loss.
The research objective described in detail in the following pages was three-fold. 
First, several botanical extracts were screened for in-vitro efficacy of affecting specific 
biomarkers and the proteasome, pertinent to hair growth regulation. These markers are 
the growth factors VEGF and KGF and the cytokine IE-la. To our knowledge, this four­
fold examination of cellular constituents, in response to a vast array of herbal extracts, is 
a unique approach to researching hair loss/growth potential remedies. The optimal 
performing extracts were then analyzed through a Design of Experiments (DOE) to 
understand effective concentration ranges and synergistic effects. The second objective 
involved incorporating the select blend of herbal components into a liposomal-based hair 
growth promoting topical solution that meets human safety criteria and product stability 
performance. Upon successful completion, the final objective was to conduct a semi- 
clinical trial testing this developed herbal-liposomal based product on actual androgenic 
alopecia subjects following modified phototrichogram protocols, using minoxidil (Extra 
Strength Rogaine®) as the benchmark, with comparison to a proprietary liposomal blend 
already clinically tested.
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CHAPTER IV- MATERIALS AND METHODS
All cell culture preparation and cell treatment was carried out using standard 
aseptic techniques in laminar flow-through hoods. All extracts were tested in duplicate 
on the same plate, and at least one additional trial was conducted using a different 
culturing and/or passage of cells, botanical extract concentration and/or reagents/kit lots. 
The screening of extracts and DOE analyses occurred from Fehmary 2005-June 2006.
A.) VEGF AND KGF ASSAYS
Mesenchymal-derived human Hair Follicle Dermal Papilla Cells (HFDPC) and 
HFDPC Growth Medium were purchased from Cell Applications (San Diego, CA, USA). 
HFDPCs were stored in liquid nitrogen until flask seeding, at which time, 15mL of 
HFDPC medium was dispensed into a 75 -cm^ (growing surface area) collagen coated 
flask (BD BioSciences, Bedford, MA, USA). A single, frozen cryovial (>500,000 cells) 
was thawed in a 37°C water hath for one minute, and the contents dispensed into the 
prepared flask, followed hy a 1-mL medium rinse of the cryovial. The newly seeded 
flask was placed in a 37°C / 5% CO2 incuhator overnight. Following cell attachment, the 
HFDPC medium was replaced with fresh medium and cells were allowed to reach 80- 
90% confluency (approximately one week). HFDPCs were then plated onto either 24- 
well or 96-well, hovine collagen type 1 (BD BioSciences, Bedford, MA, USA) coated 
plates after a Hanks Balanced Salt Solution without Ca^VMg^"  ^rinse (Fisher Scientific, 
Hanover Park, IF, USA) and detachment with trypsin/FDTA (Fisher Scientific, Hanover 
Park, IF, USA). Cells were plated at concentrations of 35,000 cells/well, 500-pF of 
medium (24-well plates) or 7,500 - 10,000 cells/well and 200-pF of medium (96-well 
plates). Cell attachment was allowed to occur overnight in a 37°C / 5% CO 2 incuhator.
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B.) IL - la  ASSAY
Proliferating human epithelial-derived kératinocytes (HEKOOl) were purchased 
from ATCC (Manassas, VA, USA) and stored in liquid nitrogen until seeding. Filter- 
sterilized culture medium was prepared with Invitrogen’s Keratinocyte Serum Free 
Medium-Ix (Carlsbad, CA, USA), supplemented with 1% F-glutamine (Invitrogen), 1% 
penicillin and 1% amphotericin b (Mediatech, Manassas, VA, USA) and 0.1-0.2 qg/mU 
Gibco Bovine Pituitary Extract (Carlsbad, CA, USA) and 17 ng/mU of Invitrogen’s 
epidermal growth factor. A frozen cell vial (600,000 cells) was thawed in a 37°C water 
bath for one minute and its contents were transferred to a centrifuge tube containing 9.0- 
mU of HEKOOl medium. Following centrifugation at 1200 rpm for 10 minutes, the 
resulting pellet was re-suspended in new culture medium and transferred to a Corning 75 
cm^ flask (Corning, NY, USA), where 80-90% confluency was reached in a 37°C / 5% 
CO2 incubator (3-4 days). Upon reaching the desired confluence, HEKOOls were rinsed 
with Hanks Balanced Salt Solution with Ca '^ /^Mg '^  ^and then detached with 
trypsin/FDTA. A HEKOOl rinse medium (Keratinocyte serum free medium, 1% 
amphotericin b, 1% penicillin and 10% Fetal bovine serum [Hyclone, Fogan, UT, USA]) 
was used to transfer cells to a centrifuge tube where pellet formation occurred at 1200 
rpm for 10 minutes. Supernatant aspiration was followed by addition of 30mF culture 
medium and plating HEKOOl occurred in 24 well cell plates (200,000 -  600,000 cells / 
500 [xF) or 96 well cell plates (32,000 cells / 200-220 pF). Cell attachment was allowed 
to occur overnight in a 37°C / 5% CO2 incubator.
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c.) EXTRACT EFFICACY TESTING
Botanical extracts were tested on plated HFDPC and HEKOOl cells for VEGF, 
KGE and IL -la  (DOE only). Briefly, extracts were prepared to a 50-mg/mL concentrated 
stock solution using dimethyl sulfoxide (Eisher Scientific, Eairlawn, NJ, USA), 99.5% 
ACS ethyl alcohol (Acros, NJ, USA) and purified water at 50%, 30% and 20% levels. 
Solvent concentrations were adjusted as appropriately for each extract’s solubility 
properties. Extract solutions were vortexed thoroughly and sonicated in a 23°C water 
bath for 10 minutes. Test solutions were prepared for each extract by diluting with the 
proper medium type under aseptic conditions. Each extract was tested in-vitro at end 
concentrations of 10 pg/mL, 1.0 pg/mL and 0.1 pg/mL. Cell culture plates were removed 
from incubation and examined under an inverted microscope (Cambridge Instruments, 
Buffalo, NY, USA) to ensure appropriate cell morphology and attachment to the culture 
plate. Under aseptic conditions, media was carefully aspirated and replaced with the 
proper amount of prepared extract. For controls, cells were treated with the same 
volume of respective media only. After addition of the extract, cell culture plates were 
returned to 37°C / 5% CO2  incubation for 24 hours. Following incubation, cell 
supernatant was removed from the cell culture wells and transferred to vials for freezing 
at -20°C until ELISA analysis.
D.) ELISA TESTING
HFDPC and HEKOOl cell supernatants were evaluated for their concentration of 
VEGF/KGF and IE I a, respectively, by ELISA. Protocols for KGF (R&D Systems, 
Minneapolis, MN, USA), VEGF (BioSource, Camarillo, CA, USA) and IL -la  
(BioSource) were followed according to the manufacturers’ instructions, with the
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exception of centrifugation of supernatants to eliminate particulates (due to minimal 
volumes and clear nature of the supernatant). Colorimetric readings from ELISA plates 
were measured on either the Wallac Victor^ 1420 Multilabel Counter (Turku, Finland) or 
the Perkin-Elmer multilabel plate reader (Waltham, MA, USA). Amount of expressed 
growth factor or cytokine was expressed as pg/mL and percent expression relative to the 
control within each plate.
E.) PROTEASOME ASSAY
Boston BioChem’s (Cambridge, MA, USA) SDS Activation Format assay was 
utilized to evaluate the ability of botanical extracts to suppress the 20S subunit activity, 
the catalytic core of all proteasome isoforms, in cell-free systems. Activity is measured 
by fluorescence readings of solutions, to which a peptidyl substrate is added, following 
core activation by sodium dodecyl sulfate. Botanical extracts were prepared the same as 
they were in the cell culture assays, but diluted to test concentrations with reaction buffer 
provided in the assay kit. One hundred pL of diluted extracts were added to 96-well 
Nunc (Rochester, NY, USA) black-wall and side multi-dish plates, followed by active 
enzyme solution (0.0998% end concentration). Diluted substrate was then added (0.1% 
end concentration) to the wells and the plates were incubated at ambient, but dark, 
conditions for thirty minutes. Fluorescence was measured with the Perkin-Elmer plate 
reader, set to an excitation wavelength of 360 nm and emission wavelength of 465 nm.
All samples were run in triplicate, including the positive controls (enzyme, substrate and 
reaction buffer), negative controls (substrate and reaction buffer only) and reaction buffer 
only. Influence of proteasome activity was determined by percentage of fluorescence 
relative to the positive control.
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F.) EVALUATION OF BOTANICAL EXTRACT PERFORMANCE
An arbitrary scoring system was developed to summarize the performance of each 
extract for each assay. The scores were summed and extracts exhibiting elevation of 
VEGF and KGF (126% - >300% of the control) and suppression of proteasome activity 
(89% - <30%) were considered possible candidate botanical ingredients for a hair 
growth-promoting product. Positive scores for each assay were deemed desirable in 
terms of biomarker performance, and the score ranges were based upon the history of 
maximal extract performance (up regulation of VFGF and KGF, relative to media 
controls; suppression of the proteasome complex relative to positive control performance 
of the proteasome and substrate) observed in early bioassay work. These selected 
extracts were then analyzed through Fusion Pro Design of Experiments (DOE) software 
(S-Matrix Corporation, Eureka, CA, USA) layouts based on testing of fixed ranges of 
each extract, either in combination or as a single ingredient. Each DOE analysis 
incorporated multiple, individually prepared replicates as a means to determine standard 
error and statistical analysis included multiple linear regression and ANOVA. Two 
DOEs were performed, with each measuring growth factor expression (VEGF and KGE), 
cytokine expression (IL-la) and proteasome activity through the appropriate cell 
treatment/assay methods described above. Each DOE analysis compared performance as 
percent relative to the control in each assay, as well actual expression levels (pg/mL) for 
each biomarker. DOE 1 consisted of five botanical extracts whereas DOE 2 evaluated 
the performance of only four extracts. A follow-up ingredient optimization study was 
also conducted, via DOE set-up and analysis, to arrive at a finalized ingredient testing 
concentration.
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G.) INGREDIENT FINALIZATION
The selected extracts were incorporated into a series of prototype bases to mimic 
potential topical delivery. A maximal extract containing prototype formulation was 
submitted for human Repeat Insult Patch Testing through TKL Research Incorporated 
(Rochelle Park, NJ, USA). Briefly, select sites on volunteers are cleaned thoroughly and 
allowed to air dry. Product soaked patches are adhered to the skin sites and are to be 
removed 48 hours later by the participant. Within 48 -  72 hours after initial patch 
application, trained clinicians who were evaluating any adverse reactions, including 
inflammation and sensitization, graded participants. Approximately two -  three weeks 
following the first challenge, treated patches are again applied to the same sites, along 
with additional new sites, with 48 hour contact time and follow-up grading within the 72 
hour application time frame. Subsequent Patch tests were also conducted on individual 
extracts to derive an approved blend of extracts of specific concentration to be utilized in 
a prepared topical formulation.
H.) LIPOSOME PREPARATION AND PRODUCT STABILITY
Incorporation of the select extracts into a lecithin-based liposomal (following and 
utilizing already established in-house protocols), leave-on topically applied product was 
inhibited by safety requirements and suggested DOE usage levels. This balance was 
achieved by extensive range testing of liposome-forming components, as well as external 
stabilizing compounds, skin penetrating agents and aesthetically pleasing ingredients. 
Trial formulations were performed following standard product development procedures 
using common lab equipment. Liposome development was enhanced through the use of 
a 110-Y Microfluidizer (Microfluidics Corp., Newton, MA, USA) to reach a desired
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particle size, which would also be stable under standard stability test conditions. 
Successful incorporation of the liposome into an applicable external phase was 
determined by macroscopic stability observations (separation, haziness, discoloration 
and/or malodor). Particle size was determined using Microtrac’s Nanotrac 150 particle 
size analyzer (Montgomeryville, PA, USA) and followed after exposure to both high and 
low temperature extremes (5°C, Ambient, 40°C and 50°C). pH stability was also 
followed after storage at low and high temperatures by allowing samples to equilibrate to 
room temperature then measured by the use of a calibrated “Basic pH Meter” (Denver 
Instrument, Arvada, CO, USA). Acceptable results for all of tbese parameters would 
determine successful incorporation of the extract blend into a liposomal-based usable hair 
growth product.
I.) MICROBIAL TESTING
Standard American Type Culture Collection (ATCC, Rockville, MD, USA) 
strains employed in preservative efficacy screening include Acinetobacter baumannii, 
Aspergillus niger, Burkholderia cepacia, Candida albicans, Enterobacter gergoviae, 
Escherichia coli, Klebsiella pneumoniae. Pseudomonas aeruginosa. Staphylococcus 
aureus and Staphylococcus epidermidis. Briefly, the hair growth prototype was 
aseptically checked for inherent microbial contamination by being plated witb microbial 
content agar and tbe number of colony forming units, f^ or bacteria, mold and yeast tallied. 
The presence for objectionable organisms (Gram negative rods/cocci. Staphylococcus 
aureus and beta-hemolytic Streptococci) was also screened. If minimal to no growth of 
contaminants was measured, the prototype was then inoculated with mold (0.5 mU/lOO g 
prototype) and bacteria/yeast inoculum (0.5 mU/100 g prototype) and tested at two, four,
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seven, ten, fourteen and twenty-eight days post inoculation by spreading (10"  ^dilution) 
inoculated product onto potato dextrose agar (mold and yeast) and microbial content test 
agar (bacteria). Self-sterilization in seven days or less is considered an adequate interval 
for efficacious microbial resistance (Access Business Group, LLC, Ada, MI, Internal Test 
Procedure, 2008).
J.) CLINICAL PROTOCOL
A general recruitment letter was sent to approximately 800 male employees at 
Amway Incorporated, seeking volunteer enrollment from those afflicted witb 
androgenetic alopecia. Exclusions included those suffering from hypertension, heart 
disease, diabetes, thyroid diseases, metabolic disorders and current, or recently stopped 
users of hair growth products (topical and ingestible products). Exclusions were not 
made for age, degree of baldness (Hamilton-Norwood, stages 1-8), nor years of balding 
but these were noted. Incentives for participation included $150.00 worth of gift cards 
to local merchants. Amway Research & Development staff screened all individuals who 
expressed interest, with initial respondents numbering approximately 120. Initial 
screenings included visual assessment and grading of the individual’s balding state, a 
topical head image (Canfield Visia CR, Canfield Scientific Inc. and Mirror Software, 
version 7.2, Canfield Imaging Systems, New Jersey, USA) and a brief questioning of 
medical/medicine history. Through attrition and medical issues, the total number of 
individuals selected for the study was 74, and this included Hamilton-Norwood scores of 
1-8 and ages 18-65. The participating individuals were divided into three cells, one for 
each test product and the cell demographics were stratified based on age range, the 
Hamilton-Norwood balding score and years of experiencing a balding condition. All
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participants were given, explained and signed Informed Consents, Patient Bill of Rights, 
and Photo Release Forms prior to study commencement.
Upon commencement of the study, beginning November, 2007, enrolled 
participants came to the Amway Research & Development Salon to have their entire 
scalp hair cut to 14”, followed by a washing with Satinique™ Gentle Daily Cleanser.
After towel drying, a global, top of the scalp “cut” image was taken with the Visia CR. 
An Area of Interest (AOI) was identified on each individual somewhere in a balding/non­
balding transition zone, with equal portions shared between the two conditions. A non­
permanent dye (Clairol® Natural Instincts 36 Midnight Black) was then applied to the 
AOI and left on for 1.5 minutes, with minimal application to the scalp. Following the 
soak time, the dye was removed with wetted gauze, and from the AOI and area of 2cm X 
2cm was clipped to a minimal length (approximately 1 mm length of hair remained 
within this zone). With a red extra fine-point permanent marker (Sanford Sharpie®, 
USA), 2 temporary dots were placed within the AOI using a flexible, plastic template. 
The center between these two reference points was measured from the left-to-right top 
pinna-scalp joint and from the bridge of the nose back. A “clipped” marked 3OX image 
was captured with the ScanHair Tablet 4701 (Biomedical Electronics, Bordeaux, France) 
camera, captured through the Hauppauge WinTV2000 (Hauppauge, NY, USA) video 
capture card. The AOI was then shaved smooth with an electronic shaver and additional 
ScanHair “shaved” images were obtained. The red marks were re-darkened and 
participants were instructed not to shampoo their hair for seventy-two hours, until the 
follow-up visit was completed. At the follow-up appointment, the temporary marks were
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relocated and re-marked as necessary. The AOI was dyed as before and washed with 
gauze, followed by ScanHair “72 hour” images.
At the seventy-two hour visit, participants were given their product in a six-week 
supply quantity, consisting of eighty-four bottles plus six extra. Each bottle contained 
1.5-mL of product, equating to one application with instructions to use twice per day with 
a four-hour minimum leave-on period. The product was to be dispensed over the entire 
scalp, w%th special emphasis on balding/thinning areas, using a massaging technique and 
allowed to air dry. Ideal application times were suggested to be once per morning and 
once per evening. Product application occurred over a 12-week period (December 2007 
-April 2008). In all, three cells were tested; Rovisomes Biotin (ROVI Cosmetics 
International, supplied by RITA Corporation, USA), a clinically tested hair growth 
prototype formula (code 586); the Access Business Group (Amway Corporation) 
developed botanical formula (code 883, Prototype 2); and Rogaine® Extra Strength 5% 
Minoxidil topical solution as a positive control (code 194).
Image analysis was performed with Image Pro Plus, version 5.1 (Media 
Cybernetics Inc., Silver Springs, MD, USA) and Access Business Group-developed 
softwares. Erom the “cut” global images, macro changes in hair coverage and/or pattern 
could be observed. Anagen-telogen ratio counts were calculated from Image Pro Plus 
enhanced images from Scan Hair “shaved” and “72 hour” photos, with “clipped” images 
serving as guides for active and non-active follicles. Growth rates (mm/72 hours) were 
also measured from Scan Hair “shaved” and “72 hour” photos with a calibrated 7 mm 
Image Pro Plus scale. AOI density measurements were calculated from “72 hour” 
photos, using the Access Business Group proprietary software. Density values correspond
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to darkened pixel detection from the captured image and are automatically calculated as 
the percent area covered within the specified frame. Pre and post-treatment values (initial 
visit and twelve week visit, respectively) were statistically compared using the t-test. All 
statistical analyses were conducted using Microsoft® Office Excel, 2003 SP3 and/or 
StatGraphics Plus for Windows, version 2.0.
Lastly, at the conclusion of the study, participants completed self-assessment 
questionnaires numerically rating the efficacy of the products, attributes of the products 
and application procedures with results statistically compared by analysis of variance 
(ANOVA). Rating values were based on a nine-point scale pertaining to likes/dislikes of 
the hair growth product and agree/disagree statements relative to the efficacy of the 
products on hair growth and hair appearance and texture. Table 1 shows the rating 
categories and corresponding point values.
Table 1-Format of Self-Perceived Questionnaire Evaluating Product Quality & Performance
Dislike
Extremely
(1)
Dislike 
Very 
M uch (2)
Dislike
M oderately
(3)
Dislike
Som ewhat
(4)
N either 
Like nor 
Dislike 
(5)
Like
Som ewhat
(6)
Like
Moderately
(7)
Like
Very
M nch
(8)
Like
Extremely
(9)
Overall
Liking
Aroma
D isagree 
Very 
Strongly (1)
Disagree
Strongly
(2)
Disagree
Moderately
(3)
Disagree
(4)
Neither
Agree
nor
Disagree
Agree (6)
Agree
M oderately
(7)
Agree
Strongly
(8)
Agree Very 
Strongly (9)
Easy 
Dispension  
Quick  
Absorption  
Enhanced  
Natural Hair 
Improved 
Hair 
Appearance 
Improved 
Texture 
Improved 
D en sity  
Concept was 
Intriguing
(5)
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CHAPTER V- RESULTS
A.) SELECTION OF BOTANICAL EXTRACTS
Composite botanical extract efficacy was calculated as the sum of trial 
performances for each bioassay, with multiple trials being run for each extract in several 
assays. Values for scoring (Table 2) were based on the effect of the extract to up or down 
regulate each biomarker, relative to a media-only control for VEGF and KGF, and an 
enzyme/substrate positive control for proteasome function ran in conjunction with each 
trial.
Table 2-Extract Scoring for in-vitro Assays
Bioassay
VEGF/KGF
Proteasome
Control Range Extract Score
>300 30
300-276 25
275-199 20
200-176 15
175-151 10
150-126 5
125-76 0
75-51 -5
50-26 -10
<25 -15
>169 -20
169-150 -15
149-130 -10
129-110 -5
109-90 0
89^^ 5
10
49-30 15
<30 20
Several of the extracts were tested multiple times (n values in Table 3) to 
understand response variability in the cell-culture systems (VFGF and KGF) and to set
the ran g e  o f  ex p ress io n  fo r sco ring  pui-poscs. I F - l a  w as on ly  ru n  fo r the  D O E  p o rtio n  o f
the research due to timing issues and controversy of the biomarker in HF regulation.
Extracts and composite scores are listed in Table 3. Of the forty-nine listed extracts,
seven were selected for potential incorporation into a usable product (Boswin 30,
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Lichochalcone, Phycojuvenine, Saw Palmetto, Shiso, Teavigo Phospholipids and Green 
Rooibos) based on having the overall highest composite scores. From the selected list of 
seven extracts, two were eliminated, one based on patent protection for using the extract, 
or a derivative of it, in another hair growth claiming product (Teavigo Phospholipids: 
epigallocatechin gallate in US Patent 106263A1) and one based on comparable 
performance (i.e. Phycojuvenine compared to Saw Palmetto) to the five remaining 
selected extracts. The final ingredients selected for optimization, and possible synergistic 
effects, were Lichochalcone, Saw Palmetto, Shiso, Green Rooibos and Boswin 30.
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Table 3- Extract Scores in Bioassays with extracts
# Extract VEGF KGF Proteasome Composite Score n
1 Amentoflavone 10 -5 20 25 14
2 Apple Extract (Appol) -20 -5 15 -10 14
3 Applephenon SH 5 0 5 10 16
4 Astaxanthin 10 30 -10 30 23
5 Astilibin -5 - 10 0 14
6 Avocutine 5 5 -10 0 17
7 Bamboo (R1563) 30 0 -10 20 17
8 Bamboo AOB (R1558) -10 30 15 35 14
9 Bamboo E 0B -C 02  (R1555) 10 15 0 25 20
10 Bamboo EOB-POl (R1560) -5 20 10 25 11
n Bamboo EOB-SOl (R1557) 0 15 -5 10 14
12 Bamboo E 0B -S 02  (R1556) 0 30 -5 25 11
13 Bamboo Essence 1 (ACCL) 20 20 -5 35 14
14 Bamboo Essence 2 (ACCL) -20 35 -15 0 14
15 Bamboo EZR-2002 (R1559) -10 35 10 35 11
16 Bamboo Stachyse (R1562) 0 15 -5 10 17
17 Boswellia serrata -10 -10 25 5 14
18 Boswellin forte 5 0 30 35 20
19 Boswin 30 30 15 25 70 17
20 Boswin 30 (5-loxin) -5 -10 20 5 22
21 Centella asiatica extracts 0 -15 -5 -20 16
22 Cocoa Extract -5 -10 -10 -25 16
23 CoQlO TPM 15 0 -10 5 17
24 Cosmoperine -20 -30 -10 -60 14
25 EllagiC Acid -20 -15 10 -25 14
26 GFS 75% 15 20 0 35 20
27 Grape Seed Oil -10 -15 -10 -35 16
28 Gravinol-S -25 20 15 10 16
29 Green Coffee Antioxidant -5 30 -5 20 14
30 Hops Oleoresin -10 -10 0 -20 14
31 Isoginketin 74% 0 -10 20 10 15
32 Kudzu Extract -5 -5 -30 -40 14
33 Lichochalcone 40 40 40 120 25
34 Luteolin -25 -10 0 -35 14
35 Phycojuvenine 30 30 -5 55 17
36 Phytavail Zn -5 -5 -5 -15 16
37 Red Clover Special -5 -20 -25 -50 8
38 Rogaine® 0 -10 -10 -20 14
39 Salvia -5 0 -15 -20 26
40 Saw Palmetto (Euromed) 30 35 -5 60 19
41 Saw Palmetto 5 45 -5 45 20
42 Shiso 5 50 -10 45 31
43 Soy Extract 15 15 -10 20 15
44 Teavigo 5 -10 20 15 16
45 Teavigo Phospholipids 25 15 10 50 14
46 Green Rooibos 0 50 -5 45 22
47 Vitagen -5 -5 -10 -20 14
48 Vital ET -5 0 5 0 8
49 Ximenynic Acid -15 15 -10 -40 20
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B.) DOE ANALYSIS
DOE 1 (Table 4) and DOE 2 (Table 5) analyses showed at least one of the 
extracts had a significant influence (ANOVA) in all four hioassays (Table 6), and 
response data did fit the regression models in all cases.
Table 4- DOE 1 Layout
Run Lichochalcone Boswin 30 Saw Palmetto Shiso Green Rooibos
1 0 0.5 1 0 0
2 0 0 1 0 1
3 0^5 0.75 0 2 5 0.25 0.75
4 0.5 1 . 1 1 0
5 1 1 0 0 0
6 0 0 1 0 1
7 0 0.5 0 1 0
8 1 0 0.5 0 1
9 1 0 1 0.5 0
10 0 0 0.5 1 1
11 0.5 0.5 0.5 0.5 0.5
12 0.75 0.25 0 2 5 0.75 0.75
13 1 1 1 0 1
14 1 0 0 1 0
15 0.5 0 0 0 0
16 0 J 5 0.75 0.75 0.25 0 2 5
17 0.5 0 1 1 1
18 0 2 5 0.25 0.75 0 2 5 0.75
19 1 0 0 1 0
20 0 0 0 0 0
21 0.75 0 2 5 0 2 5 0 2 5 0.75
22 0 2 5 0 2 5 0.25 0 2 5 0.75
23 0 1 0.5 0 1
24 0 1 1 0 0.5
25 1 0 0 0.5 1
26 0.5 1 0 1 1
27 0 2 5 0.75 0.25 0.75 0 2 5
28 0 0 1 1 0
29 0.5 0.5 0.5 0.5 0.5
30 0 2 5 0 2 5 0 2 5 0.25 0 2 5
31 0 0.5 1 0 0
32 0 0 1 1 0
33 0.5 1 0 1 0
34 0 2 5 0.75 0.75 0.75 0.75
35 0 2 5 0 2 5 0.75 0 2 5 0 2 5
36 0 0 0 1 1
37 1 0 1 0 0.5
38 1 0.5 0 0 1
39 0 1 0 0 0
40 1 1 0 1 0.5
41 0 1 1 1 1
42 1 1 1 1 1
43 0 0.5 0 0 1
44 0 1 0 0 0
45 0 0 0 I 0
46 0 0 1 0 0
47 0 0 0 0 1
48 1 0 0 0 0
49 0 0 0 0 0
50 0 0 0 0 0
47
Table 5- DOE 2 Layout
Run Lichochalcone Saw Palmetto Shiso Green Rooibos
1 0.1 0.5 0 0
2 0.1 0.5 25 0
3 0.1 12.75 0 0
4 0.1 25 25 0
5 0.1 25 0 12.5
6 0.1 0.5 0 25
7 0.1 0.5 0 25
8 0.1 0.5 25 25
9 0.1 12.75 25 25
10 0:1 25 12.5 25
11 0.2 6.625 18.75 6.25
12 0.2 18.875 6.25 6.25
13 0.2 6.625 18.75 18.75
14 0.2 18.875 18.75 18.75
15 0.3 25 0 0
16 0.3 12.75 12.5 12.5
17 0.3 12.75 12.5 12.5
18 0.3 25 25 25
19 0.4 18.875 18.75 6.25
20 0.4 18.875 6.25 6.25
21 0.4 6.625 6.25 18.75
22 0.4 18.875 18.75 18.75
23 0.5 0.5 25 0
24 0.5 0.5 0 0
25 0.5 0.5 25 0
26 0.5 25 12.5 0
27 0.5 25 25 0
28 0.5 25 25 0
29 0.5 25 0 12.5
30 0.5 25 25 12.5
31 0.5 0.5 0 25
32 0.5 0.5 25 25
33 0.5 25 0 25
34 0.5 25 12.5 25
35 2.875 6.625 18.75 6.25
36 2.875 18.875 6.25 6.25
37 2.875 18.875 6.25 18.75
38 2.875 18.875 18.75 18.75
39 5.25 25 0 0
40 5.25 0.5 12.5 12.5
41 5.25 12.75 12.5 12.5
42 5.25 12.75 12.5 12.5
43 5.25 25 25 25
44 7.625 18.875 18.75 6.25
45 7.625 18.875 6.25 6.25
46 7.625 6.625 6.25 18.75
47 7.625 18.875 18.75 18.75
48 10 0.5 0 0
49 10 0.5 25 0
50 10 25 12.5 0
51 10 25 25 12.5
52 10 0.5 25 25
53 10 25 0 25
54 10 25 0 25
M u ltip le  lin ear reg ressio n  analysis  in d ica ted  th a t several o f  the  ex trac ts  h ad  sign ifican t 
impacts on either up or down regulation (% control) of the specific hiomarkers.
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Table 6- Results of DOE Analyses 1 & 2 (L= Lichochalcone, GR= Green Rooibos, P=Saw Palmetto,
___________________________________________ S= Shiso)___________________________________________
DOE 1
Bioassay df Value p value n Regression Models (All contributing extracts listed, p < 0.05)
VEGF 3 0.59 < 0.0001 50 5.493 -  3.823 (Ex L) + 2.942(Ex GR)" -  1.251 (Ex. P * Ex S)
KGF 2 0.61 < 0.0001 50 17.433 + 1,667(Ex L) -  1,886(Ex Lf 
25361 -  3236(Ex L) -  649(Boswln 30) -  771 (Ex L * Boswin
Proteasome 6 0.80 < 0,0001 50 30) + 652(Ex L * Ex GR) + 771 (Boswin 30 * Ex S) -  660(Ex S 
* Ex GR)
IL -la ' 2 0.16 0.02 50 3.877 + 0.79(Boswin 30) -  0.076(Ex P * Ex GR)
DOE 2
VEGF* 3 0.64 < 0.0001 54 4.756 -  1.321 (Ex L) -  1.513(Ex P) -  1.416(Ex L * Ex P)
KGF 3 0.91 < 0.0001 54 36.78404 -28.36144(Ex L) -  5.70125(Ex P) - 4.57404(Ex GRf
0.162 + 0.044(Ex L) -  0.030(Ex L)" + 0.002(Ex L * Ex GR) +
Proteasome* 6 0.98 < 0.0001 54 0.002(Ex L * Ex P) + 0.002(Ex L * Ex S) + 0. 002(Ex GR * Ex
P)
5.271 + 0.202(Ex L) + 0.213(Ex P) -  0.242(Ex L)^- 0.091 (Ex 
L ’ Ex P)IL-1a' 4 0.70 < 0.0001 54
For VEGF, Lichochalcone was a down-regulator in both DOE studies. Saw Palmetto, 
either in conjunction with Shiso (DOE 1) or Lichochalcone (DOE 2), also had a similar 
effect. Higher concentrations of Green Rooibos negatively affected YEGE production. 
KGE expression (pg/mL) had relatively high baselines in both DOEs, but Lichochalcone 
had contradictory effects. In DOE 1, a dose-dependent effect was observed for 
Lichochalcone, with higher concentrations leading to suppression of YEGE production. 
Lichochalcone, on the other hand, was predominantly suppressive of KGE in DOE 2, as 
was Saw Palmetto and higher concentrations of Green Rooibos.
Proteasome function was definitely suppressed by Lichochalcone and Boswin 30, 
both separately and in combination, in DOE 1. Interestingly, when Lichochalcone or 
Boswin 30 were combined with Green Rooibos and Shiso, respectively, proteasome 
function was enhanced, while Green Rooibos and Shiso in combination down-regulated
* Data required transformation prior to an a lysis. For IL-1a, DOE 1, e  raised to ttie regression  
m odel listed; for DOE 2, th e transformation invoived the sum  of - 3 .1 9 4  + e  raised to the m odel 
sum . For VEGF in DOE 2, the VEGF su m  dep icted  w a s squared.
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proteasome activity, possibly indicative of antagonistic effects of these compounds. In 
DOE 2, a higher concentration of Lichochalcone led to a reduction of proteasome 
function, while all other significant combinations tended to slightly up-regulate the 
proteasome. Lichochalcone, Boswin 30 and Saw Palmetto enhanced IL -la  expression. 
Saw Palmetto in combination with Green Rooibos suppressed IL -la  expression (DOE 1), 
as did Saw Palmetto with Lichochalcone (DOE 2). Since Boswin 30 demonstrated 
proteasome inhibition, hut was less effective than Lichochalcone, as well as being a slight 
up regulator of IL -la, it was dropped from consideration as a potential hair growth 
promoting extract.
When the DOE optimization study was conducted, a total of seventeen 
combinations of extracts were screened, with ranges of each extract derived from DOE 1 
and DOE 2. From these studies, and corresponding analysis, three combinations of 
extracts were determined to he suitable for product incorporation, whereas only one 
combination had a positive influence in more than one of the hioassays. The final 
optimal blend of extracts consisted of Lichochalcone at 2.5 pg/mL, Green Rooibos at 
12.5 pg/mL, Saw Palmetto at 4.5 pg/mL and Shiso at 12.5 pg/mL. From the elicited 
dose cellular responses, it was decided to treat these as tenfold concentrations in an actual 
use product, thereby resulting in levels of 0.25% for Lichochalcone, 1.25% for Extracts 
Green Rooibos and Shiso and 0.45% for Saw Palmetto.
C.) INGREDIENT FINALIZATION
Due to time constraints, a maximally concentrated botanical prototype 
formulation (Prototype 1) was submitted for Repeat Insult Patch Testing to aüe out 
severe irritancy issues and possible allergic sensitization occurrences in humans.
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Prototype 1 consisted of 1% each of extracts Green Rooibos, Saw Palmetto and Shiso and 
0.20% of Lichochalcone and 5% each of three skin penetration enhancers. Of the 109 
subjects challenged and re-challenged with Prototype 1, one individual definitively 
showed a sensitization response, along with five other potential participants. This 
formulation also caused significant irritation. As a result, Prototype 1 was not approved 
for further testing, in accordance with inherent corporate standards. Mild irritation 
responses are acceptable for research continuation, but when severe irritation arises, 
coupled with potentially widespread sensitization, re-formulation is mandated.
Subsequent submissions to TKL Research included: the vehicle of Prototype 1 only; 
individual extracts along with the vehicle; reduced levels of both individual extracts and 
penetration enhancers; and ultimately, diluted extracts only, tested individually. Through 
the process of elimination, it was determined that the excessively high concentrations of 
the skin penetration enhancers, in combination with the maximal concentration of the 
botanical extracts, led to the sensitization and irritancy issues. The final approved usage 
levels of each extract were: Lichochalcone at 0.25%, Green Rooibos at 1.0%, Saw 
Palmetto at 0.45%, and Shiso at 1.25%. The skin penetration enhancers were capped at 
0.4% usage levels.
D.) LIPOSOME PREPARATION & PRODUCT STABILITY
The last hurdles of extract incorporation into a testable hair growth product were 
assembling extract-containing liposomes into a final formulation and achieving product 
stability in terms of liposome size, pH and aesthetic character. A final formula was 
developed with tolerable levels of hydrophobic extracts (Lichochalcone and Saw 
Palmetto) incorporated into the lipid membrane of the liposome, while the hydrophilic
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extracts (Green Rooibos and Shiso) were placed within the aqueous core of the liposome. 
The remaining portions of each extract, up to their allowable levels, were placed within 
either the water external phase or oil external phase, so as to achieve maximal 
concentration. The final product. Prototype 2, is shown in Table 7 with select ingredient 
ranges listed due to the proprietary and patent pending technology tested. Prototype 2 
was successfully prepared in the lab, with the liposomal phase undergoing three passes in 
the microfluidizer to achieve the desired particle size of 100 nm -  300 nm.
Table 7- Formulation of Prototype 2
Phase A (W ater External Phase)
Chemical Name 
Purified water
Diethylene glycol monoethyl ether
Dimethyl Isosorbide
Shiso
Green Rooibos
1.2.3-Propanetroil
End Phase A 
Phase B (Oil External Phase)
Polyoxyethylene Oleyl Ether
1.3-Butanediol
1.3-Dioxolan-2-one, 4 -methyl 
Lichochalcone
Saw Palmetto 
Denatured Ethanol
End Phase B 
Phase C (Liposome Phase)
Concentration
qs
0 .1 - 0 5 %  
0.1 -0 .5%  
0.6250%  
0.9000%  
i a - 4 # %
0 . 1 - 2 0 %  
0.1 -  1.0%  
0 . 1 - 1 0 %  
0.2125%  
0.2250%  
10-15%
1,3-Butanediol 5 .0 -8 .0 %
Phosphatidlycholine 4 Ü -L 0 %
N-Oleoyl Phytosphingosine 0 .1 -0 .2 %
Beta-Sitosterol 0.01 -0 .5%
Mixed Tocopherols 0 .0 1 -0 .1 %
Saw Palmetto 0.2250%
Lichochalcone 0.0375%
Shiso 0.6250%
Green Rooibos 0.1000%
Purified water
End Phase C
Phenoxyethanol, Methyl-, Propyl- & Ethylparaben 0 .5 -1 0 %
Arginine 0.01 -0 .02%
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A multi-environment stability was then conducted with the prototype stored in 
glass jars. At subsequent evaluation points, the prototype’s pH and aesthetic properties 
(Table 8) were evaluated, as was liposome particle size (Figure 4) and these were 
compared to specification range and initial production values. The initial production pH 
was below the specification range, most likely due to inadequate pH adjustment during 
manufacturing. For the 5°C condition. Prototype 2 retained all acceptable attributes 
throughout the test. Ambient stored samples exhibited a slight alteration in odor but were 
satisfactory for color and appearance attributes. At both elevated temperature 
conditions, noticeable discoloration occurred, as did a very slight thickening of the 
product. The fragrance lost most of its tea-like character, which gave way to an oil-based 
solvent scent.
Table 8- Stability Profile of Prototype 2 Formula
Aesthetic Attributes: color, appearance & odor*
Acceptable
Amber, translucent liquid w/ ethanolic, tea-like fragrance
Acceptable 
Acceptable 
Acceptable
Amber w/ more medicinal odor 
No change 
No change
Amber, more viscous & naore solvent notes 
No change
Light, dirty brown color; more translucent w/ more solvent 
character
Light, dirty brown color; more viscous w/ solvent character
Specification
pH
S.7-7.5
Initial 5^2
1 Month @ 5°C 5.6
2 Months @ 5°C 5.5
3 Months @ 5°C 5.5
1 Month @ Ambient 5.6
2 Months @ Ambient 5.4
3 Months @ Ambient 5.4
1 Month @ 40°C 5.5
2 Months @ 40°C 5.3
3 Months @ 40°C 5.2
1 Month @ 50°C 5.5
 ^ T he formulator ev a lu a tes  a esth etic  attributes with com p arison s m ade to the 5°C  sa m p les.
 ^ Im m ediately after production the m easu red  pH w a s out of the specification  range of 5 .7  -  7 .5 . 
This w a s d ue to an in adequ ate am ount of ad ded  arginine to e lev a te  the pH. All su b seq u en t  
v a lu es w ere then out of specification . T he b iggest drop in pH (3 m onths at 40°C ) to 5 .2 2  is not 
abnorm al for this product type. An ad eq u ate  am ount of arginine would be n eed ed  to co m p en sa te  
for this drop to k eep  th e product within th e specification  range after eleva ted  tem perature storage .
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For the ideal particle size range (Figure 4), there was no significant difference 
between the initial sample and all stability samples (ANOVA, p  = 0.34). In fact, for all 
particle sizes (data not shown) measured (0.95 nm -  6540 nm, n =52), there was no 
significant difference between any of the eleven samples (ANOVA, p  = 1.0).
Ideal Liposome Particle Size Range Totals Following Stability Testing
100
I  80
I
°  60 
0)
g>
(0
EC 40
■ -  20
F
Initial 1 Montti @ 3 Months @ 1 Month @ 3 Months @ 3 Months @ 1 Month @ 
5C 5C Amb Amb 40C 50C
Stability Conditions
Figure 4- Liposome Particles in the Ideal Size Range for Prototype Stability Samples (+/- SE)
Prototype 2 was intrinsically clean with less than one hundred colony- forming 
units of aerobic bacteria, yeast and mold isolated during plate counts. For the self­
sterilization portion of the microbial testing, performance was robust for eliminating 
bacteria, yeast and mold. With bacteria and yeast inoculation, product self-sterilization 
o ccu rred  in  less th an  tw o  days, w h ile  w ith  m old , se lf-s te riliza tio n  to o k  less th an  fou r 
days. All results indicate Prototype 2 is a well-preserved formulation and meets industry 
standards for microbial safety.
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F.) CLINICAL STUDY
Cell demographics are detailed in Tables 9 - 11 .
Table 9 - Product 586 User Demographics with users in bold 
eventually dropping from the study. Adjusted values include only 
those individuals who remained in the study for the full 12 weeks.
Cell #1- Rovisomes
Number Age Range N-H Balding Score Years Balding
101 39-49 8 20
102 29-39 3 5
103 4& j9 7 20
104 18-29 4 2
105 3&49 5 5
106 29-39 6 10
107 39-49 4 10
108 39-49 7 18
109 39-49 7 15
110 49-59 6 5
111 39-49 5 23
112 29-39 7 10
113 39-49 8 10
114 49-59 7 35
115 29-39 3 20
116 29-39 8 10
117 18-29 7 9
118 29-39 8 10
119 3&49 3 1
120 49-59 6 20
121 29-39 5 2
122 3&49 8 15
123 29 39 2 8
124 29 39 1 1
125 3&49 8 10
126 29-39 4 3
Mean 5.72 11.8
Adjusted 5.63 11.46
Median 39-49 6 10
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Table 10- Product 883 User Demographics with users in bold
eventually dropping from the study. Adjusted values include only
Cell #2- Prototype 2
Number Age Range N-H Balding Score Years Balding
201 59-69 4 10
202 39-49 5 20
203 49-59 7 10
204 3 9 4 9 2 5
205 39-49 4 2
206 49-59 3 15
207 18-29 8 10
208 3 9 4 9 6 20
209 59-69 7 20
210 39-49 7 10
211 3 9 4 9 7 15
212 3 9 4 9 8 18
213 49-59 8 20
214 3 9 4 9 8 25
215 49-59 6 6
216 3 9 4 9 4 10
217 49-59 6 7
218 3 9 4 9 5 7
219 49-59 7 5
220 3 9 4 9 7 15
221 29 39 5 3
222 39-49 8 20
223 29-39 6 4
224 29-39 3 5
Mean
Adjusted
Median 3 9 4 9
5.875
5T8
6
11.75
11.39
10
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Table 11- Product 194 User Demographics with users in bold
eventually dropping from the study. Adjusted values include only
Cell #3- Rogaine® 5 % Minoxidil
Number Age Range N-H Balding Score Years Balding
301 3^49 6 18
302 3949 8 25
303 49-59 8 20
304 49-59 7 22
305 49-59 7 20
306 49-59 4 3
307 49 59 4 5
308 49-59 6 19
309 49-59 7 10
310 49-59 5 10
311 49 59 8 20
312 29-39 6 3
313 3949 2 5
314 3949 4 17
315 49-59 5 12
316 49-59 8 17
317 3949 3 10
318 29-39 7 8
319 3949 7 15
320 49-59 6 5
321 49-59 7 10
322 29-39 7 12
323 3949 3 10
324 29-39 7 16
Mean 5j^ 13.13
Adjusted 5.82 13.27
Median 49-59 6.5 12
Representative global “Cut”, AOI “Clipped” and “Shaved” and “72 Hour” follow 
up images from all three cells at the initial visit are depicted in Figures 5 - 8 .
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a. Cell 586 b. Cell 883 c. Cell 194
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Tables 12-14 represent the change in global hair density per individual in each
cell, with dropped participants omitted.
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Table 12- Change in Density over 12 weeks for Rovisomes
Number Pre-Treatment Density Post-Treatment Density % Change
102 2.46 2.75 11.8%
103 1.14 2.27 99.1%
105 3T0 2.95 -2.0%
106 2.23 -13.6%
107 3.60 6.14 70.6%
108 122 3.03 -5.9%
109 227 4.62 103.5%
110 3.77 1027%
111 2.56 2.83 10.5%
112 2.91 2.09 -28.2%
113 1.48 2.00 35.1%
114 1.95 1.57 -19.5%
115 2.84 1.88 -33.8%
116 2.96 1.62 -45.3%
117 2 in 2.90 40.1%
118 3jW 406 44%
119 2T7 3.31 19.5%
120 1.81 2.Ci4 12.7%
121 3.00 180 26.7%
122 I j# 1.90 2.2%
123 1.54 129 113.6%
124 3.71 6.58 77.4%
125 1.37 2.06 50.4%
126 2JU 5.69 146.3%
Table 13- Change in Density over 12 weeks for Prototype 2
Number Pre-Treatment Density Post-Treatment Density % Change
201 1.97 5J2 165.0%
202 3.01 2^7 -4.7%
203 4jG 5.74 18.4%
204 6.51 7.16 10.0%
205 2J0 4^8 51.1%
206 3J8 3 j# 14.8%
207 5.02 7.27 44.8%
208 4.40 4^2 5.0%
209 2.11 3^0 61.1%
210 2J9 3^5 145%
211 1.67 1.63 -2.4%
212 123 3.57 10.5%
213 0.71 0.72 1.4%
214 1.21 1.62 33.9%
215 1.44 1.62 12.5%
216 4.12 4.44 7.8%
217 2.53 2.60 2.8%
218 2J9 2J8 16.3%
219 2.96 3.74 26.4%
220 1.78 2^0 23.6%
221 2.04 2.15 5.4%
223 2J5 3^9 30.5%
224 5.01 5.12 2.2%
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Table 14- Change in Density over 12 weeks for Rogaine'
Number Pre-Treatment Density Post-Treatment Density % Change
301 1.66 1.97 18.7%
302 3J8 3.77 -03%
303 2A0 3J6 504%
304 2,41 2^4 93%
305 1.53 1.71 11.8%
306 1.85 3A8 884%
307 2J0 2 j# 7^%
308 1.71 1.66 -2.9%
310 2.48 2J6 113%
311 3J# 48.4%
312 3JK 5.50 673%
313 6TG 7A3 249%
314 1J2 2.33 91.0%
315 3.11 3J& 48%
316 1.34 1.69 264%
317 5.16 649 20n%
318 2.68 3J2 383%
319 2.84 2jG -03%
320 1.40 1.43 24%
322 1,95 2A6 2hO%
323 3^# 3^9 03%
324 1.93 2JW 203%
The average change in density for the Rovisomes material was 32.4%, while that 
for Prototype 2 and Rogaine® were 24% and 25.4%, respectively. Pre- and post­
treatment comparisons (t-test) revealed usage of all three compounds caused significant 
up-regulation in hair density (Rovisomes, p = 0.01; Prototype 2 , p  = 0.0008; and 
Rogaine®' p  = 0.0002). When the percent changes were statistically compared (ANOVA) 
between the compounds, no significant difference existed (Table 15).
Table 15-ANOVA of Percent Change in Hair Growth Density over 
12 weeks for all 3 Cells (Values transformed [logio(% change^)] to correct 
____________________ for non-normal distributions)._____________________
 Source Sum of Squares df Mean Square F-ratio P-valuc
Between Groups 6.45 2 3.23 2.18 0.12
W ithin Groups 101.92 69 1.48
Total 108.37
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From the Anagen-Telogen ratio counts, the calculated percentage of hair follicles 
in the Anagen stage are broken down by cell and are displayed in Tables 16-18.
Table 16- Change in Anagen Hair Follicles over 12 weeks for Rovisomes
Number Pre-Treatment Anagen Post-Treatment Anagen % Change
102 38T4 4936 27.16%
103 55.19 5930 7.27%
105 6038 61.06%
106 24.01 38.28 59.43%
107 3&28 7539 97.47%
108 42.39 6133 45.86%
109 67.51 88451 31.25%
110 40.53 74.07 82.75%
111 6T54 64.91 2.16%
112 28.57 39.38 3734%
113 62.14 45.13 -27.37%
114 57.31 69.95 22.06%
115 5&89 45.54 -10.51%
116 77.18 70.90 -8.14%
117 60.59 57.97 -4.32%
118 70.53 67.08 ^.89%
119 5637 4939 -12.38%
120 5265 71.57 35.94%
121 55.04 56.11 1.94%
122 5630 4830 -14.59%
123 738 2733 246.83%
124 56.00 82.46 47.25%
125 49.74 31.48 -36.71%
126 6208 84.47 33.91%
Table 17- Change in Anagen Hair Follicles over 12 weeks for Prototype 2
Number Pre-Treatment Anagen Post-Treatment Anagen % Change
201 4339 8430 94.27%
202 72.70 41.03 -43.56%
203 69.32 87.26 25.88%
204 8138 9330 14.03%
205 45.02 6939 54.13%
206 58.14 7943 36.62%
207 71.61 8930 24.98%
208 65.28 8&91 23.94%
209 2339 54.23 95.85%
210 43.P9 49.79 15.28%
211 50.10 6638 3349%
212 34.50 59^2 7338%
213 19.49 3732 94.05%
214 3232 4332 32.60%
215 Kt32 30.16 84.80%
216 6246 6832 1048%
217 57.21 89 91 57.16%
218 50.81 75.55 48.69%
219 66.59 77.03 15.68%
220 30.16 3220 23.34%
221 45.16 43.41 -3.88%
223 59.59 6936 16.40%
224 78.71 8530 838%
6 1
for Rogaine
Number Pre-Treatment Anagen Post-Treatment Anagen % Change
301 47.55 64.35 35.33%
302 52.53 57.10 8.70%
303 35.37 69.80 97.34%
304 41.44 53.71 29.61%
305 30.52 34.37 12.61%
306 44.42 71.12 60.11%
307 50.05 80.49 60.82%
308 45.73 64.82 41.75%
310 50.59 69.61 37.60%
311 57.68 90.71 57.26%
312 71,35 88.00 23.34%
313 76.26 88.59 16.17%
314 34.46 41.53 20.52%
315 51.72 71.18 37.63%
316 55.53 34.40 -38.05%
317 77.22 91.20 18.10%
318 46.78 64.51 37.90%
319 48.19 54.72 13.55%
320 29.06 18.83 -35.20%
322 36.29 44.69 23.15%
323 71.20 81.49 14.45%
324 34.06 41.53 21.93%
All three-test products exhibited a positive increase in the number of anagen hair 
follicles over the twelve-week period. Rovisomes yielded an average increase of 
30.05%, while that for Prototype 2 was 36.37% and for Rogaine®, 27.03%. Statistically, 
all increases in the number of anagen hair follicles for each product were significant 
(Rovisomes, p  = 0.01 ; Prototype 2, /? = 0.00004; and Rogaine®, p = 0.0001). Comparison 
between the three cells, showed no significant difference (Kruskal-Wallis) in the ability 
to promote anagen follicle induction {p = 0.54). Data transformation in the form of logio 
(jc^ ) was required prior to analysis to achieve a normal distribution.
The last measure of performance determined from the AOI Scan Hair images was 
growth rate. Before and after treatment growth rate values are displayed in Tables 19-21.
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Table 19- Change in Growth Rate over 12 Weeks for Rovisomes
Number Pre-Treatment Growth Rate (mm/72hrs) Post-Treatment Growth Rate (mm/72hrs) % Change
102 0.68 0.57 -19.30%
103 0.46 0^0 8.00%
105 0.45 0U8 -18.42%
106 0.40 0^3 -21.21%
107 0.63 0.54 -16.67%
108 0.41 0.44 6.82%
109 0.58 0.64 9.38%
110 048 0.60 20.00%
111 0.51 0^3 3.77%
112 0^6 0.61 8.20%
113 0.48 0^6 14.29%
114 0.57 CU6 -58.33%
115 0.59 0^2 -13.46%
116 0.57 0J7 -54.05%
117 0J2 0J2 0.00%
118 0^9 0^3 6.35%
119 0.62 0J8 20.51%
120 0.47 049 498%
121 0.65 0.61 -6.56%
122 0.59 049 -20.41%
123 0.41 0^9 30.51%
124 0.54 0.60 10.00%
125 0.37 0.44 15.91%
126 0.71 0^5 -9.23%
Table 20- Change in Growth Rate over 12 Weeks for Prototype 2
Number Pre-Treatment Growth Rate (mm/72hrs) Post-Treatment Growth Rate (mm/72hrs) % Change
201 0^2 0.65 25.00%
202 0.70 0.73 4.29%
203 0.63 0 J 9 25.40%
204 0.60 0.67 11.67%
205 0.55 0J 8 41.82%
206 0.50 0.55 10.00%
207 0^2 0.95 1595%
208 0.62 0.77 24.19%
209 0.51 0.62 21.57%
210 0^4 0^3 -1.85%
211 0.55 0.35 -36.36%
212 0.55 0.67 21.82%
213 0.38 0.42 10.53%
214 0.45 0.45 0.00%
215 0.64 0.67 4.69%
216 0.74 0^6 -24.32%
217 0.54 0.66 22.22%
218 0.43 0.59 37.21%
219 0.50 O^ W 20.00%
220 04 9 0.63 28.57%
221 0.47 0.55 17.02%
223 0.63 O j# 3.179%
224 0.57 0^ 6 -1.75%
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Table 21- Change in Growth Rate over 12 Weeks for Rogaine®
Number Pre-Treatment Growth Rate (mm/72hrs) Post-Treatment Growth Rate (mm/72hrs) % Change
301 (149 0A2 -14.29%
302 0J3 0A5 -24.66%
303 0.64 0.66 3.13%
304 0A7 0A7 0.00%
305 0.41 0A3 4.88%
306 0A8 056 16.67%
307 0A8 0^3 31.25%
308 0J9 0.40 2.56%
310 0^0 0.42 -16.00%
311 0.67 0J2 7.46%
312 0^3 081 28.57%
313 0.66 0.67 1.52%
314 0A9 0^3 28.57%
315 0^3 0A3 0.00%
316 0.67 0^7 0.00%
317 Oj6 0A3 -5.36%
318 0.47 0^3 34.04%
319 0.57 0A9 3A1%
320 0.48 0.44 -8.33%
322 0.48 0.46 -4.17%
323 0A9 0A3 8.16%
324 0^3 0J7 -30.19%
For the Rovisomes material, the average change in growth rate was -3.33% over 
the twelve-week treatment period. Both Prototype 2 and Rogaine® had positive increases 
in growth rate over the same time span, 12.21% and 3.06%, respectively. The change in 
growth rate for all cells was not significant (Rovisomes, p = 0.90; Prototype 2 ,p  = 0.07; 
Rogaine®, p  = 0.67) at the 95% confidence level. When the change in growth rate of all 
three-test products was compared (ANOVA, Table 22), a significant difference was 
found to exist between Rovisomes and Prototype 2 (p = 0.016).
Table 22- ANOVA of Percent Change in Growth Rate over 
12 Weeks for all 3 Cells
Source Sum of Squares df Mean Square F-ratio P-value
Between Groups 0.29 2 0.14 3.92 0.02
Within Groups 2.40 66 0.04
Total 2 ^ #
In Figure 9, the average density, percent anagen and growth rates are depicted for 
each test material, showing the overall efficacy of each product in promoting hair growth.
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Figure 9- Comparison of Average Values (+/- SE) for Objective Measurements
for all 3 test products
From Figure 9, it is evident overall density increased from baseline to study conclusion 
for all three-test products. Also, the number of hair follicles in the anagen stage 
increased for all test variables, but for growth rate, Rovisomes was stagnant, while 
Prototype 2 and Rogaine® showed slight increases.
As a means of looking for trends within the cells of the three test products, and to 
verify adequate stratification of cell demographics, correlation tables were created for 
identifying potential relationships. These are shown in Tables 23 - 2 5 ,  and possible 
strong associations (r > 0.5) are depicted in bold.
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Table 23- Correlations within Rovisomes Cell (All r values greater than +/- 0.5 bolded)
Category AgeDecade
NH
Score
Years
Bald
Ini. % 
Ana Ana
% Change 
Ana
Ini
Dens
12wk
Dens
Age Decade 
NH Score 
Years Bald 
Ini. % Anagen 
12wk % Anagen 
% Change 
Anagen 
Ini Density 
12wk Density 
% Change 
Density
1
0.253
0.490
0.056
0.228
-0.031
-0.413
-0.189
0.117
I
0 3 8 0
0377
-0.027
-0.481
41286
-0.514
41289
1
0.163
1 M 5
-0.150
-0.285
41498
41325
I
0.555
-0.750
1W 3
0.039
-0.074
I
-0.080
0.331
0.584
0 3 0 5
1
-0.013
0.313
0.409
I
0.490
41328
1
0.637
Table 24- Correlations within Prototype 2 Cell (All r values greater than + /- 0.5 bolded)
Age NH Years Ini. % 12wk% % Change Ini I2wk
Decade Score Bald Ana Ana Ana Dens Dens
Age Decade 1
NH Score 0.002 1
Years Bald 0.244 0.474 1
Ini. % Anagen -0.435 -0.486 -0.361 I
I2wk % Anagen -0.147 -0.438 -0.474 0.746 1
% Change 0.576 0.227 a œ w -0.727 -0.140 1
Ini Density 41358 -0.443 0.834 0.701 -0 498 I
12wk Density -0.223 -0.396 0.715 0.762 41268 0.889 I
% Change 
Density 0381 -0.080 41058 -0.194 0 1 6 9 0.449 -0.162 0.287
Table 25- Correlations within Rogaine® Cell (All r vaines greater than + /-  0.5 bolded)
Age NH Years 12wk % % CW tge Ini /2w&
Decade Score Ana Ana Ana Dens Dens
Age Decade 1
NH Score 0.009 1
Years Bald 0.194 0.625 1
Ini. % Anagen -0.182 -0.501 -0.341 1
12wk % Anagen -0.053 -0.452 -0.301 0.777 I
% Change 0.138 -0.021 0.049 - a m # 0.563 1
Ini Density -0.247 -0.536 -0.294 0.805 0.674 0.034 I
12wk Density -0.318 -0.525 41415 0.793 0.742 036 3 0.914 1
% Change -0.153 -0.092 -0.217 -0.034 0.152 0.317 -0.186 0 199Density
Each cell exhibited both positive and negative strong correlations, particularly in
the Hamilton-Norwood score relative to percent anagen and density values. The initial
and twelve week percent anagen categories also had strong relationships with density
values and percent anagen changes. The age decade, years balding and the percent
change in anagen had minimal relatedness for each of the three test products. Scatter
plots (data not shown) of all interacting categories verified the absence of influential
points in creating potential false correlations.
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The results from the self-perceived assessments evaluated at the conclusion of the 
study are compared in Table 26.
Attribute /  Product Rovisomes Prototype 2 Rogaine® ANOVA p-value
Overall Liking 6.57 5.74 6#0 0.13
Aroma 6.00 57# 5#6 070
Easy Dispensing 7.48 7.68 7.76 0#6
Quick Absorption 7.10 7.26 679 0.26
Enhanced Natural Hair 5T6 4#8 5#5 074
Improved Hair Appearance 5.19 4.74 573 077
Improved Texture 5.14 4.53 5.06 070
Improved Density 57# 4.37 5.28 070
Concept was Intriguing 6#I 67^ 775 072
For the each of the above attributes, there was no significant difference in rating value 
across the three product types. For Prototype 2, overall liking and aroma of the product 
was rated below Rovisomes and Rogaine®, but was at near parity with Rogaine® for 
dispensing onto the scalp and directionally better than the other two variables at 
absorbing into the skin following application. In terms of improving hair growth and the 
physical characteristics of the hair (appearance, texture and density). Prototype 2 was 
consistently rated lower than both Rovisomes and Rogaine®. This was also the case for 
the perceived intrigue regarding the product concept.
67
CHAPTER VI: DISCUSSION
The screening of extracts across four bioassays resulted in the creation of a 
testable and usable hair growth prototype formulation to potentially treat androgenic 
alopecia. The novelty of screening botanical samples for efficacy in VEGF, KGF, 
proteasome and XL-la bioassays to develop an end product was enhanced by the use of 
DOE software. Incorporation of the approved extracts into a liposome formulation 
proved to be successful, since particle size and aesthetic attributes were acceptable even 
after a long-term stability test.
However, flaws were also exposed in cell culturing techniques and use of an 
arbitrary scoring system to successively screen botanical extracts in a rapid fashion.
Since much of the human HE biology work is done on cells obtained from elective, 
cosmetic surgical procedures (Lu et al., 2006; Xiong and Harmon, 1997; Philpott et al., 
1990), it is necessary to have full accounts of the age, gender information of the donors, 
as well as isolation locations of commercially available HE cells. During the course of 
the in-vitro screening process, variability was often observed in the responses elicited by 
the botanical samples. As the screening of extracts for this project occurred over a one- 
year span, the cell culturing practices were evolving due to an increasing staff and 
corporate emphasis. Within that time, it was discovered much of the initial HEDPC 
culture work was conducted on either female-derived tissue, and/or had been undergoing 
varying periods of frozen storage states prior to flask and plate seeding as well as 
different cell-passage techniques. Such conditions may have influenced how the 
screened extracts performed on each assay. In addition, if HEDPC cells have been 
allowed to progress into later passages of culture (6-t-), they undergo transformation and
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have little resemblance to in-vivo counterparts (Randall, 1996). Therefore, if all extracts 
had been screened consistently, in terms of HFDPC type and passage, it is totally 
plausible to have arrived at a completely different blend of extracts and to have 
eliminated some the variability observed in cytokine and growth factor expression. 
Furthermore, expression levels of the growth factors were significantly reduced from 
initial runs (data not shown). Ideally, all extracts should have been tested the same 
number of times to fairly assess variability and performance. Unfortunately, time and 
cost were negative factors prohibiting this from occurring. The cell-free proteasome 
assay was not affected by any of this variability.
The addition of the IL -la  assay to the extract screening process may have also 
acutely focused overall scoring results, but this assay was included just prior to the DOE 
analyses. Before the use of IL -la, a dihydrotestosterone assay was utilized as an extract- 
screening tool. This androgen has pertinent regulatory control over hair growth and can 
eliminate scalp hair fiber production (Mulinari-Brenner and Bergfield, 2001). This assay 
was stopped due to inconsistencies with the ELISA kit (data not shown) and the 
discovered ineffectiveness of topical applications inhibiting dihydrotestosterone activity.^ 
IL -la  is still somewhat controversial in terms of hair loss causation and cures, with a 
large body suggesting it inhibits hair growth (Stenn and Paus, 2001) and causes atrophy 
of the HE in in-vitro culture experiments (Mahe et al., 1996). Recent work, however, 
indicates it may up regulate VEGF and KGF, which are favorable to hair growth (Boivin 
et al., 2006). Despite its controversial status, IL -la  still remains a critical cytokine in 
terms of treatment, since it is a good marker for inflammation, a condition not to be
® O utside consultation  led to this d iscovery.
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overly promoted during topical treatment. When using this marker in the DOE, the focus 
was on selecting extracts at concentrations that did not up regulate IL -la  in a substantial 
way, but rather, were comparable to media treated (control) cells.
For all DOE experiments, cell source and passage were known and documented to 
coincide with actual male-pattem baldness, undergoing two cryofrozen states maximally 
and treated at passages four and five only. In DOE I, the contradictions in extract 
performance compared to the initial screening process were evident for VEGF (Extracts 
Lichochalcone, Green Rooibos and Saw Palmetto) and KGF (Lichochalcone), while 
proteasome performance matched nicely. Since VEGF and KGF are cell-based assays, 
and the proteasome assay is strictly enzyme-based, it is possible the combination of the 
living systems and the aforementioned discrepancies in technique contributed to the 
variation observed between screening and DOE analysis. Similar trends were seen in 
DOE 2, thereby indicating the DOE experiments have greater validity at elucidating 
extract activity in the assays than the initial screening process.
In regards to the extracts selected for incorporation into Prototype 2, all four have 
noted properties slated to be beneficial to humans. Additionally, this select blend of 
extracts incorporated into a topical treatment for hair loss, specifically targeting the 
modulation of VEGE, KGE, IL -la  and the proteasome, is unique and novel.
Rooibos, a native South African legume {Aspalathus linearis), is commonly used 
as a tea and has been found to contain relatively high concentrations of polyphenolic 
antioxidants. Such compounds can inhibit free-radical damage, common in coronary 
diseases and cancers. Eolklore traditions have claimed Rooibos as curing colic and 
soothing various skin allergies (Erickson, 2003). Additional benefits include microbial
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resistance, anti-aging and inflammation mediators in the oral cavity and within muscle 
and joint tissue (Cosmetics Design, 2006).
Lichochalcone, specifically Lichochalcone A, is licorice root extract from 
Glycyrrhiza inflata. It has long been used as a traditional medicine in eastern cultures, 
treating digestive ailments and allergic conditions (Shibata, 2000). Benefits of applying 
Lichochalcone topically include reduced irritation from both mechanical and ultra-violet 
stimuli (Kolbe, et al., 2006) as well as acting as an anti-inflammatory treatment (Cui, et 
ah, 2008). Lichochalcone A, as supplied for this research, has been noted as also having 
anti-microbial properties and inhibiting the hair growth related enzyme, 5-a reductase, as 
well as androgen activity (Barnet Products Corporation, 2007).
Shiso extract is isolated from Perilla ocymoides leaves and has been generally 
used for both medicinal and dietary purposes in the Far East. Claims include anti­
bacterial efficacy, treatments for digestive disturbances and diseases of the skin, with 
clinical data indicating improvement of dermatological conditions (Barnet Products 
Corporation, 2005).
Saw Palmetto lipid extract is isolated from the berries of Sabal serrulata, a native 
small palm of the southern United States. It is a Native American traditional medicine 
and is a common botanical treatment for benign prostate hyperplasia. Inherent 
phytosterols mimic the androgens testosterone and dihydrotestosterone and infer anti- 
androgenic properties to the extract (Euromed, 2000).
Eormation of liposomes containing maximally allowed levels of these extracts 
was not possible due to incompatibility and inverse solubility characteristics between 
Lichochalcone, Green Rooibos, and possibly Saw Palmetto. In addition, the hydrophilic
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and hydrophobic properties of the extracts, at the highest allowed concentrations, 
impeded liposome formation, resulting in higher concentrations of lecithin usage to 
mediate hydrophobic extract incorporation. Despite the limiting extract concentration 
factor obtained from the Repeat Insult Patch Testing, all four selected extracts were 
incorporated into Prototype 2 by utilizing all three phases (oil, water and external) during 
development. Three passes through the microfluidizer resulted in optimal liposome 
particle size, which remained relatively constant throughout elevated temperature 
stability testing. This successfully demonstrates stable liposomes and stable external 
phases in the prototype formulation.
The pH profile was out of the speeification range, but that oeeurred during the 
production process most likely due to insuffieient addition of Arginine, which was being 
utilized as a pH booster. An additional twenty-five to fifty pereent increase in Arginine is 
expected to bring the final product pH into the ideal slightly acidie (Jung et al., 2006) 
specifieation range. Since the overall pH range varied only slightly throughout the 
stability test, it is reasonable to expect that a formulation within the proper pH range 
would also remain stable over time and temperature variations.
The diseolorations of the produet at higher temperatures, as well as the fragranee 
character, are not atypical results for this product type. Color often degrades at higher 
temperatures, but the changes observed in Prototype 2, at both 50°C and 40°C, still 
allowed the formulation to retain a brownish character, with no evident precipitation. 
Likewise, the fragrance character changed slightly at the elevated temperatures, most 
likely due to slight rancidity of lipid components in the formula. By incorporating an 
actual fragrance into the prototype, this could easily be masked.
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Through the novelty of screening botanical extracts in four bioassays, and the 
optimization analyses by the DOEs, a potential hair growth promoting formulation has 
been developed. In the process, modification of cell-culturing techniques and 
understanding of the variability in living systems has led to additional insight on hair 
follicle dynamics. Future botanical extracts, in addition to Lichochalcone, Shiso, Saw 
Palmetto and Green Rooibos, may be more efficiently screened for efficacy on in-vitro 
hair follicle systems, thereby leading to additional testable in-vivo products targeting hair 
growth restoration.
Minoxidil, the active ingredient in Rogaine® Extra Strength, has been known to be 
a promoter of scalp hair growth, as a result of topical application, since the early 1980’s 
(Vanderveen, et ah, 1984). Since it is only one of two Food and Drug Administration 
(FDA) approved drugs to treat hair loss (Leavitt, et., al., 2005), it has become the 
benchmark for topically applied products designed to combat androgenetic alopecia. 
Finasteride, the other approved compound, is orally administered (Merck & Co, 
www.propecia.com., 2007) and its efficacy is irrelevant, as such, to the scope of this 
research.
Early examination of minoxidil’s effectiveness at treating hair growth in 
androgenetic alopecia shows limited success. Only three of five minoxidil users 
experienced notable hair growth using a 5% concentration, with only one rated as having 
“appreciable restoration of larger, thicker pigmented terminal hair” (Vanderveen et ah, 
1984, p. 418) and the other two noticing a slight increase in terminal hairs. The other two 
individuals had no hair regrowth, but these were 1% minoxidil users. These evaluations
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included both subjective evaluations and scalp biopsy analysis with emphasis on hair 
shaft diameter (Vanderveen et ah, 1984).
More recent examinations of minoxidil’s performance included trials comparing 
varying concentrations of minoxidil (Olsen et ah, 2002) and minoxidil delivered in 
different forms (Shin et al., 2007 and Olsen et ah, 2007). A 5% versus 2% minoxidil 
concentration study showed the higher active test product to be more efficacious than the 
lower concentrated material. After forty-eight weeks of usage in men aged 18-49, the 5% 
material resulted in 45% greater non-vellus hair regrowth in the AOI compared to 2% 
minoxidil results. Additional parameters, assessed by both the patients and expert 
evaluators, all indicated the 5% minoxidil was better at increasing scalp hair coverage, 
and having positive impacts on self-perception due to increased hair growth/regrowth.
The AOI hair counts were done by macro photography with manual conversion of 
terminal hairs to acetate overlays, followed by image software counting (Olsen et al., 
2002)
When 5% minoxidil was incorporated into a bydroalcobolic foam base and tested 
versus a placebo, a significant increase in hair counts occurred in the minoxidil version. 
This 16-week study included 352, 18-49 year old males, with Hamilton-N orwood balding 
scores ranging from III-V, and with an average duration of balding being fourteen years. 
Target area hair counts in the AOI (using similar measurement techniques as the previous 
study above) increased by approximately 345%, over the placebo, by the end of the 
sixteen-week study. Subjective self-assessments were also significantly better for those 
using the active product, with 70.6% of minoxidil users claiming an improved condition 
to the placebo’s 42.4%. In neither case, the age, balding score, nor years balding bad any
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influence on the results. Lastly, global scalp photographs, when rated by expert graders, 
also showed significant increases in hair growth for minoxidil users versus the control 
patients (Olsen et ah, 2007).
A study employing similar evaluation techniques as used in this research was 
conducted with 5% minoxidil combined with the skin penetration enhancer tretinoin. A 
topical solution containing just 5% minoxidil served as the control. A total of thirty-one 
males between 28-45 years of age, with Hamilton-N orwood balding scores ranging from 
III-V, participated. No significant difference existed between the two treatments in total 
hair counts, anagen hair ratios, growth rate and self-assessments (Shin, et ah, 2007).
A joint clinical-like study between Synymed Incorporated and the University of 
California San Francisco evaluated a non-liposomal cream-based herbal topical treatment 
on androgenetic alopecia males. This herbal blend included fennel, polygonum, mentha, 
chamomile, thuja and hibiscus. Twenty-four participants were using either the 7.5% 
herbal cream or a placebo cream. All subjects were under 55 years of age, and had 
balding scores between III-IV. The parameters evaluated were total and terminal hair 
counts, hair length and total hair weight. Average percent changes were significant for 
total and terminal hair counts (77.4% for active vs. 3% placebo and 169.4% for active vs. 
33.9% placebo, respectively), while those for total hair weight and average hair length 
were not statistically different between the test material and the placebo (Greenberg and 
Katz, 1996).
The Rovisomes material tested in this research project contains the active 
ingredients of biotin (Vitamin H), linoleic acid (Vitamin F), Vitamin E-acetate, D- 
panthenol (Provitamin B5) and caffeine all incorporated into a liposome carrier system to
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enhance skin penetration. Results of a limited twenty-four week study showed increases 
in hair density and the number of hair follicles in the anagen stage of the hair cycle. For 
the six males participating, a 9.4% increase in density was calculated, while anagen hair 
follicles increased by 5.3% and telogen follicles decreased by 16%. Self-assessment 
scores, converted to a 9-point scale used within this body of research, were as follows: 
formulation consumption- 7.0; formulation spreading- 7.4; hair quality- 7.2; hair volume- 
6.9; and overall rating- 7.2. Statistical comparisons are not mentioned and separation of 
the self-assessment scores between male and female users is not given (Rovi Cosmetics, 
“An innovative serum for increased hair density” is an internally submitted report).
The value of the research conducted herein can only be appreciated if placed in 
the context of previous attempts to promote hair growth in those suffering from 
androgenetic alopecia, as referenced above. The herbal blend of Lichochalcone, Shiso, 
Green Rooibos and Saw Palmetto incorporated into a liposomal vehicle has shown 
comparable success to the leading topical treatment, Rogaine® Extra Strength (5% 
minoxidil). Hair density, number of anagen (active) follicles and growth rates increased 
from study commencement to its conclusion for all three test products, and these 
increases were all statistically significant. While the Rovisomes material was 
directionally better at increasing hair density, the Prototype 2 formulation yielded 
directionally better results than Rogaine® and Rovisomes for increasing anagen hair 
follicles and improving growth rates, with the change in growth rate being statistically 
different versus Rovisomes. It is reasonable to conclude all three-test products, to some 
degree, had hair growth promoting effects as evidenced by the objective measurements.
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As this research included expanded age ranges (18-59), the whole spectrum of 
Hamilton-N orwood balding scores (1-8) and longer durations of experiencing a balding 
condition (1-35), the elicitation of positive objective responses is excessively burdened. 
However, the Prototype 2 material increased hair density by 24%, promoted anagen hair 
follicle presence by 36.4% and boosted hair growth rates by 12.2%. These changes, 
though not as impressive as some of the figures cited above, are respectable given this 
work’s broader demographics and differences in measurement techniques. This is further 
supported by Rogaine’s® performance- a 25.4% increase in density, 27% increase in 
anagen follicles and only a 3.1% increase in growth rate. Even though the Rovisomes 
material performed directionally better with a 32.4% increase in density and 30.1% 
increase in anagen hair follicles, its negative growth rate of -3.3%  and absent discussion 
pertaining to measurement methodology and limited male participation question the 
relevant efficacy of this product.
Subjectively, even though not significantly different, the Prototype 2 formulation 
trended downward with the exception of product dispensation and absorption of material 
into the scalp, where it was rated as second best and first, respectively. Even though true 
objective measurements can remove personal bias, for hair growth promoting treatments, 
the subjective perception is the critical criteria for ultimately determining product success 
(Piérard et al., 2004). In this regard. Prototype 2 was deficient, particularly in terms of 
positively influencing hair quality. However, a recent editorial by Dominique Van Neste, 
contrasts objectivity to subjectivity in hair growth evaluation, with detection of a 
worsening balding condition taking longer to recognize using subjective evaluations than 
objective assessments. Eurthermore, the self-perceived evaluation is deemed “the least
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effective” assessment tool while a contradictory notation between objective and 
subjective values in a study comparing the two benchmark products, Rogaine® and 
Finasteride, highlights this discrepancy (Van Neste, 2008). Participants must be given 
the tools to self-evaluate, as well as an appropriate amount of time. In this study, 
individuals were not officially given before and after global images of their scalp to 
decide on their product’s efficacy. Self-evaluation in a mirror and commentary from 
casual observers were the tools used to rate product performance. Neither tool may be 
extremely accurate, and the latter may artificially inflate performance should it be 
suggestive of an increase in hair growth (Van Neste, 2008). Furthermore, the protocol of 
cutting the entire scalp hair to 14” length, and maintaining this length throughout the 
study, does not lend itself to a comprehensive self-evaluation since changes in hair 
density, active follicles and growth rate cannot be accentuated at the normal hair length. 
All three-test products were subject to these potential impedances of self-assessment, and 
as a result, the above ratings could potentially be skewed.
From the correlation tables, there appears to be no major revelations regarding 
demographic stratification or product influence on the balding condition. For instance, in 
the Rovisome’s group, a strong negative correlation (-0.514) exists between balding score 
and hair density. Since higher the balding score, the less hair present, it is reasonable to 
conclude density will also be minimal in advanced balding states. A similar, though 
positive, pattern (0.625) exists in the Rogaine® cell for the number of years balding and 
Hamilton-Norwood score. Inspection of relationships between the percentage of follicles 
in anagen over time and density changes are reasonable. Having a relatively large 
number of follicles in anagen at the conclusion of the study coincides with having a
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larger percentage of follicles in anagen at the study onset. This was the case for all 
products and these were all potentially strong positive correlations (0.555 for Rovisomes,
0.746 for Prototype 2 and 0.777 for Rogaine®). Given the length of time required to 
notice changes in hair loss (Van Neste, 2008) it is also not surprising to have negative 
correlations with initial anagen follicles and the change in the number of anagen follicles 
over a three-month period. These were strong for both Rovisomes (-0.750) and Prototype 
2 (-0.727). Finally, if the number of follicles in anagen is high, then density should also 
be greater, as was the case for Rovisomes (0.584), Prototype 2 (0.701 and 0.762) and 
Rogaine® (0.674 and 0.742).
The in-house clinical portion of this research utilized equipment and computer 
software already available to the research team. Even though convenient, the on-hand 
technology did not allow for the evaluation and measurement of all non-invasive 
parameters deemed essential for tracking hair growth response to topical treatment. 
Generally, hair growth analysis methods should be able to capture hair density 
(fibers/square area), hair fiber diameter, hair growth rate and the anagen-telogen ratio 
(Hoffmann, 2001). Hair fiber diameters were not measured due to variability in image 
quality, limits on the magnification of the AOI’s and software measuring capabilities. 
Hair density was captured and measured as pixel concentration within the AOI. Anagen 
and telogen ratios, as well as growth rates, were manually tagged on digital images and 
were again influenced by image quality. More automated techniques are available, 
notably the TrichoScan system, which combines epiluminescent microscopy and 
complete digital analysis to track all essential changes in hair growth (Hoffmann, 2001 
and Hoffmann, 2005). However, due to cost issues and availability, such noted methods
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and technology could not be employed in this study. Furthermore, the adaptations 
described here were applied to all product cells and analysis photos, so bias of 
methodology was limited. It is also worthwhile to note systems such as TrichoScan, even 
though popular for clinical analysis, still have noted detractors (Van Neste and Trueh, 
2006), with implication that no tool for hair growth analysis is flawless.
Additional factors involved in this protocol include modifications to the 
traditional phototrichogram and contrast enhanced phototrichogram methods. In both of 
these procedures, the AOI is minutely, but permanently tattooed so as to be able to 
definitively relocate it throughout the study duration. The hair within the AOI is also 
temporarily dyed up to twelve minutes so as to artificially pigment unpigmented hair 
such as vellus or gray hairs. Vellus hairs can then be differentiated from terminal hairs 
by measuring hair diameters (Hoffmann, 2001 and Van Neste, 2001). The protocol 
employed in this research was restricted to non-invasive techniques and involved 
capturing coordinate measurements from the bridge of the nose to the point of ear 
attachment and marks made with “permanent” ink. Marked locations would rarely 
remain for the three-day follow-up measurements, let alone the full twelve weeks. Hair 
dyeing was performed but left on for only two minutes, since any longer duration resulted 
in excessive scalp staining, even after wash out. The darkening of the skin within the 
AOI impeded accurate density measurements, and counting of anagen-telogen follicles. 
Any future analysis should consider permanent tattooing to hallmark AO Is and more 
uniform dyeing techniques to ensure complete hair color transformation without scalp 
penetration.
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The clinical portion of this study incorporated the botanically derived and 
liposomal-based Prototype 2 formulation, with comparisons made to the liposomal 
Rovisomes and the topical gold-standard treatment, Rogaine®. All three products 
exhibited success at improving hair density, increasing the number of anagen follicles or 
increasing the rate at which scalp hair grew. From an objective analysis viewpoint, all 
three-test products produced significant improvement in hair density and the number of 
anagen follicles, compared to baseline values. Prototype 2 and Rogaine® both increased 
growth rate from baseline measurements, but with no statistical significance.
Subjectively, Prototype 2 was the lowest rated product for improving hair quality. Since 
this was the first attempt to validate the efficacy of this patent-pending technology in-vivo 
any future work should aim to improve its aesthetic properties. Likewise, the in-vitro 
claim that this specific blend of Lichochalcone, Shiso Extract, Saw Palmetto and Green 
Rooibos modulates VEGF, KGF, IE-1 a and the Proteasome, as they relate to hair growth, 
should be verified for in-vivo proof of concept. Should that claim prove to be successful, 
coupling future clinical assessments with improved techniques and technology, could 
potentially brand Prototype 2 as a topical treatment to treat androgenetic alopecia.
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